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SUSTAINED DRUG DELIVERY SYSTEM 1, 2 , 3, 4 
Oral drug release system is the most popular route, which is due in part to 
the ease of administration and to the fact that gastrointestinal physiology offers 
more flexibility in dosage form design than most other routes. With the 
concomitant recognition of the therapeutic advantages, greater attention has been 
focused on the development of controlled or extended release drug delivery 
systems. The first sustained release tablets were made by Howard Press in New 
Jersey in the early 1950's.  
 
The first tablets released under his process patent were called 'Nitroglyn' 
and made under license by Key Corp. in Florida. The plethora of oral controlled 
release products in the market place, for example in 1998, the U.S Food and Drug 
Administration (FDA) approved 90 oral controlled release products. From 1998 to 
2003 an additional of 29 new drug applications that used controlled release 
technologies and 12 of them were based on matrix systems were approved. 
 
Sustained release, sustained action, prolonged action, controlled release, 
extended action, timed release, depot and repository dosage forms are terms used 
to identify drug delivery systems that are designed to achieve a prolonged 
therapeutic effect by continuously releasing medication over an extended period 
of time after administration of a single dose. 
 
Sustained release formulation is an important program for new drug 
research and development to meet several unmet clinical needs. There are several 
reasons for attractiveness of these dosage forms: Provides increased 
bioavailability of drug product, Reduction in the frequency of administration to 
prolong duration of effective blood levels, reduces the fluctuation of peak, 
concentration and side effects and possibly improves the specific distribution of 
the drug. 
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If one were to develop an ideal drug delivery system, two pre-requisites 
would be required:  
 
Firstly single dose for the duration of treatment whether for days or weeks 
as with infection, diabetes, arthritis or hypertension etc. 
 
Secondly it should deliver the active entity directly to the site of action 
minimizing the side effects. In general, the goal of sustained release dosage form 
is to maintain therapeutic blood levels of drug for extended period; this is usually 
accomplished by attempting to obtain zero-order release kinetics from the dosage 
form.  
Difference between conventional and sustained release dosage form 
 
 Figure.1  
There are certain considerations for the preparation of extended release 
formulations:  
¾ If the active compound has a long half-life, it is sustained on its own. 
¾ The pharmacological activity is not directly related to its blood levels, 
¾ The absorption of the drug involves an active transport and  
¾ The active compound has very short half-life then it would require a large 
amount of drug to maintain a prolonged effective dose. The above factors 
need serious review prior to design. 
INTRODUCTION  
 
   3 
 
Sustained drug delivery is used to describe a pharmaceutical dosage form 
formulated to retard the release of a therapeutic agent so that its appearance in 
systematic circulation is delayed and/or prolonged and its plasma profile is 
sustained in duration. The onset of its pharmacological action is often delayed and 
duration of its therapeutic effect is sustained. 
 
 Zero-order release constitutes drug release from the dosage form that is 
independent of the amount of the drug in the delivery system (i.e., a constant 
release rate). Sustained-release systems generally do not attain this type of release 
and usually try to mimic zero-order release by providing drug in a slow first-order 
fashion. (i.e., Concentration-dependent)  
 
Controlled release products are formulated to release active ingredient 
gradually and predictably over long period. These formulations potentially 
provide for greater effectiveness in the treatment of chronic conditions through 
more consistent delivery of the medication, reduced side effects, greater 
convenience, and higher levels of patient compliance due to a simplified dosage 
schedule, compared with those of immediate-release drugs. 
 
RATIONALE OF SUSTAINED DRUG DELIVERY 
The main objective to formulate an active pharmaceutical ingredient in an 
extended or modified drug delivery system is related to its pharmacokinetics. An 
appropriate formulation can make the absorption, distribution, metabolism and 
elimination (ADME) profile of a drug much more favourable. This change of the 
ADME can have a profound impact on many aspects of the clinical use of the 
drug from patient compliance and convenience to its very efficacy, tolerance and 
safety parameters. 
 
ADME     »  Original pKa profile 
Extended drug delivery  »  New pKa profile (Convenience,  
  tolerance, efficacy and safety) 
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Sustained release can be achieved by, 
• Incorporating the drug in a carrier system 
• Altering the structure of the drug at the molecular level 
• Controlling the input of the drug into the bio-environment to ensure a 
programmed and desirable bio-distribution. 
 The primary objectives are to ensure safety and to improve efficacy of 
drugs as well as patient compliance. This is achieved by better control of plasma 
drug levels and less frequent dosing. 
ADVANTAGES AND DISADVANTAGES OF ORAL SUSTAINED 
RELEASE DELIVERY SYSTEM 
ADVANTAGES 
• The extended release formulations may maintain therapeutic 
concentrations. 
• The use of extended release formulations avoids the high blood 
concentration. 
• Extended release formulations have the potential to improve the 
patient compliance. 
• Reduce the toxicity by slowing drug absorption. 
• Increase the stability by protecting the drug from hydrolysis or 
other degradative changes in gastrointestinal tract. 
• Minimize the local and systemic side effects. 
• Improvement in treatment efficacy. 
• Minimize drug accumulation with chronic dosing. 
• Usage of less total drug. 
• Improve the bioavailability of some drugs. 
• Improve the ability to provide special effects. 
Ex: Morning relief of arthritis through bed time dosing. 
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DISADVANTAGES 
• High cost of preparation. 
• The release rates are affected by various factors such as food and 
the rate of transit through the gut. 
• Some differences in the release rate from one dose to another dose 
but these have been minimized by modern formulations. 
• Extended release formulation contains a higher drug load and thus 
any loss of integrity of the release characteristics of the dosage 
form. 
• The larger size of extended release products may cause difficulties 
in ingestion or transit through gut. 
• Sometimes the target tissue will be exposed to constant amount of 
drug over extended period results in drug tolerance. 
 
MULTIPARTICULATE DRUG DELIVERY SYSTEMS5 
The market for drug delivery system has come a long way and will 
continue to grow at an impressive rate. Today’s drug delivery technologies enable 
the incorporation of drug molecules into a new delivery system, thus providing 
numerous therapeutic and commercial advantages. Multiparticulate drug delivery 
systems provide several advantages including greater flexibility and adaptability 
of microparticulate dosage forms which gives clinicians and those engaged in 
product development powerful new tools to optimize therapy. Therefore, such 
systems are growing rapidly in popularity. 
 
DESIGN OF MULTIPARTICULATE DRUG SYSTEMS5 
The purpose of designing multiparticulate dosage form is to develop a 
reliable formulation that has all the advantages of a single unit formulations and 
yet devoid of the danger of alteration in drug release profile and formulation 
behaviour due to unit to unit variation, change in gastro-luminal pH and enzyme 
population.  
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A generally accepted view is that multiparticulate systems perform better 
in-vivo than single unit systems, as they spread out throughout the length of the 
intestine causing less irritation, enjoy a slower transit through the colon and give a 
more reproducible drug release. Coated multiparticulates, often referred to as 
‘pellets’ or ‘beads’, commonly form the basis for a wide range of modified-release 
dosage forms. The benefits of multiparticulates are as follows: 
 
1. Minimizing irritant effects- whole, non-disintegrating tablets can 
potentially lodge in restrictions within the gastrointestinal tract, causing the 
release of drug to be localized and thus cause mucosal damage should the drug 
possess irritant effects. This potentially harmful effect can be minimized with 
multiparticulates. Since their small size reduces the likelihood of such entrapment, 
while the drug concentration is spread out over a large number of discrete 
particles. 
 
2. Reducing the consequences of imperfect coatings - film coatings, 
deposited using a spray technique, can potentially possess imperfections (such as 
pores) that could compromise the performance of modified-release dosage forms. 
Traditional coated tablets can be problematic in this regard since the whole dose 
could potentially be released quite rapidly if such imperfections (in the coating) 
exist. With multiparticulates, such a risk is greatly reduced since an imperfect 
coating on one or two pellets (out of 50-200 that constitute a single dosage unit) is 
likely to have little effect in terms of lack of benefit, or even harm, to the patient.  
 
3. Capitalizing on small size (typically 0.5-2.0 mm) - gastrointestinal 
transit times can be somewhat erratic for non-disintegrating tablets (especially as a 
result of food effects); particles smaller than about 2.0 mm can pass through the 
constricted pyloric sphincter even during the gastric phase of the digestion process 
and distribute themselves more readily throughout the distal part of the 
gastrointestinal tract. 
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4. Reducing the impact of poor coating uniformity - film-coating processes 
are incapable of ensuring that every entity (tablet, pellet, etc.) within a batch of 
product will receive exactly the same amount of coating. With a tablet, the 
complete dose of drug is contained in that dosage unit, so any tablet-to-tablet 
variation in the amount of coating applied can result in variable drug release from 
dosage unit to dosage unit.  
 
5. The types of process used for coating multiparticulate are renowned for 
achieving better uniformity of distribution of the coating material. A further 
advantage relates to the possible problem of ‘dose dumping’ resulting from a 
defect in a film coat. With multiparticulate, because the total dosage unit is made 
up of a large number of discretely coated particles, a defect in one pellet will only 
‘dump’ a small fraction, say 1/200th, of the total unit dosage. This is likely to have 
no pharmacological consequences. In contrast, a defect in a coated monolithic 
tablet could release 24 hours worth of drug into a patient in just a few minutes. 
 
Although multi-unit systems are more complicated to formulate and 
manufacture, they provide many advantages over single-unit modified release 
systems.  
a) Their physicochemical characteristics remain unaltered for long periods 
allowing long term storage. 
b) They protect encapsulated drug from enzymatic or pH-dependent 
degradation. 
c) They are suitable for industrial production. 
d) They can be formulated to provide constant drug concentration in the 
blood or to target drugs to specific cells or organs. 
e) They can also be formulated to treat local diseases that require a   
sustained concentration of the drug at a particular site. e.g: gingival, subgingival, 
periodontal and adjacent tissues in the treatment of pathologies such as gingivitis 
and periodontitis. Besides ease of local administration, they do    not have to be 
removed after the treatment period. 
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f) These systems are less dependent on gastric emptying rate, showing less 
subject variability in gastrointestinal transit time and dietary state. There is a 
lower tendency for local irritation as the drug is more widely distributed in the GI 
tract. In addition, because each unit functions as an individual modified release 
system, failure of a few units is less dangerous than the failure of a single-unit 
system, and reduces the possibility of dose dumping. The flexibility of 
programming defined position and release rates, into (potentially) each individual 
unit, provides considerable clinical advantages in delivering complex release 
profiles. 
 
HYDROGEL BEADS6 
Hydrogels are polymeric networks that absorb large quantities of water 
while remaining insoluble in aqueous solutions due to chemical or physical cross-
linking of individual polymer chains. 
 
Hydrogel Beads are highly cross linked hydrophilic spherical particles 
ranging from 0.05- 2.00 mm. It consists of natural or synthetic polymer in which 
the active pharmaceutical ingredients are cross liked with cross-linking agent to 
form a network of matrix.  
 
It have been widely used of their advantageous properties such as non-
toxicity, biocompatibility, biodegradability ability to modify the properties of 
aqueous environment, capacity to thicken, emulsify, stabilize, encapsulate, swell 
and to form gels, films. 
 
They are three dimensional hydrophilic polymeric networks which absorb 
and retain 10–20% (an arbitrary lower limit) up to thousands of time of water or 
biological fluid than their dry weights. Hydrogels may be chemically stable or 
they may degrade and eventually disintegrate and dissolve. To avoid this 
dissolution/ degradation, cross-linking is introduced within the hydrogels.  
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They have been considered to be useful in medical applications. Many 
structural factors (e.g. charge, concentration and pKa of the ionisable group, 
degree of ionization, crosslink density and hydrophilicity) influence the degree of 
swelling of ionic polymers. In addition, properties of the swelling medium (e.g. 
pH, ionic strength and the counter ion and its valences) affect the swelling 
characteristics. In recent years, much attention has been given on the development 
of hydrogels from natural, biodegradable and biocompatible polymeric materials. 
 
POLYMER FOR DRUG DELIVERY 
The use of biodegradable polymeric carriers for the drug delivery systems 
has gained a wide interest, mainly for their biocompatibility and among the 
microparticulate systems,  microspheres show a special importance for providing 
sustained action. Hydrophobic polymeric networks such as poly (lactic acid) 
(PLA) or poly (lactide-co-glycolide) (PLGA) which have limited water-absorption 
capabilities, while hydrophilic hydrogels exhibit many unique physicochemical 
properties that make them advantageous for biomedical applications including 
drug delivery. For example, hydrogels are excellent candidates for encapsulating 
bio-macromolecules including proteins and DNA due to their lack of hydrophobic 
interactions which can denature these fragile species. 
 
 In addition, compared to commonly used hydrophobic polymers such as 
PLGA, the conditions for fabricating hydrogels are relatively mild. Gel formation 
usually proceeds at ambient temperature and organic solvents are rarely required. 
In-situ gelation with cell and drug encapsulation capabilities further distinguishes 
hydrogels from the other hydrophobic polymers. 
 
 Hydrogels can be prepared from natural or synthetic polymers. Although 
hydrogels made from natural polymers may not provide sufficient mechanical 
properties and may contain pathogens or evoke immune/ inflammatory responses, 
they do offer several advantageous properties such as inherent biocompatibility, 
biodegradability, and biologically recognizable moieties that support cellular 
activities. Synthetic hydrogels, on the other hand, do not possess these inherent 
bioactive properties. Fortunately, synthetic polymers usually have well-defined 
structures that can be modified to yield tailorable degradability and functionality. 
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CHARACTERISTICS OF IDEAL POLYMER SYSTEM41 
1. It should be chemically inert and compatible with the environment. 
2. It should be non-toxic. 
3. It should be easy and inexpensive to fabricate. 
4. It should be good mechanical strength. 
5. It should have acceptable shelf life. 
 
NATURAL POLYMERS AND SYNTHETIC MONOMERS USED IN 
HYDROGEL FABRICATION  
Natural polymer 
1. Chitosan 
2. Alginate  
3. Fibrin  
4. Collagen  
5. Gelatin 
6. Hyaluronic acid 
7. Acrylic acid (AA) 
8. Dextran  
 
Synthetic monomer: 
1. Hydroxyethyl methacrylate (HEMA) 
2. N-(2-hydroxypropyl) methacrylate (HPMA) 
3. N-vinyl-2-pyrrolidone (NVP) 
4. Vinyl acetate (VAc) 
5. Methacrylic acid (MAA) 
6. Polyethylene glycol acrylate/methacrylate (PEGA/PEGMA) 
7. Polyethylene glycol diacrylate/dimethacrylate 
(PEGDA/PEGDMA) 
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SODIUM ALGINATE42 
Alginate is a water-soluble linear polysaccharide extracted from brown 
seaweed and is composed of alternating blocks of 1–4 linked α-L-guluronic and β-
D-mannuronic acid residues. The structure of alginate shows of mannuronic and 
guluronic acid residues and the binding between these residues in alginate. 
Because of the particular shapes of themonomers and theirmodes of linkage in the 
polymer, the geometries of the G-block regions, M-block regions, and alternating 
regions are substantially different. Specifically, the G-blocks are buckled while 
the M-blocks have a shape referred to as an extended ribbon. If two G-block 
regions are aligned side by side, a diamond shaped hole results. 
 
Structure of alginates shown that polymer has a chain of two guluronic acid (G) 
monomers and two mannuronic acid (M) monomers, with (1–4) linkages. 
 
Structure of alginate 
 
 
Figure.2 
This hole has dimensions that are ideal for the cooperative binding of 
calcium ions as in case of calcium ion cross-linking. The homopolymeric regions 
of β-D-mannuronic acid blocks and α-L-guluronic acid blocks are interdispersed 
with regions of alternating structure (β-D-mannuronic acid–α-L-guluronic acid 
blocks). The composition and extent of the sequences and the molecular weight 
determine the physical properties of the alginates. 
 
INTRODUCTION  
 
   12 
 
Alginates (poly-saccharides) are known to be haemocompatible and do not 
accumulate in any organs of the human body. It has been reported that sodium 
alginate can be cross linked with formaldehyde. The chemical reaction was 
between hydroxyl groups of sodium alginate and formaldehyde. Because of its 
skeletal component of the algae, it has the nice property of being strong and yet 
flexible. Alginic acid can be either water soluble or insoluble depending on the 
type of the associated salt.  
 
Alginates are established among the most versatile biopolymers, used in a 
wide range of applications. The conventional use of alginate as excipient in drug 
products generally depends on the thickening, gel-forming and stabilizing 
properties. At low pH hydration of alginic acid leads to the formation of a high-
viscosity"acid gel". Alginate is also easily gelled in the presence of water after 
cross-linking with formaldehyde. Dried beads re-swell, creating a diffusion barrier 
decreasing the migration of small molecules.  
 
Alginate is currently widely used in food, pharmaceutical. The properties 
of alginate utilized in these products are thickening, stabilizing, gel-forming, and 
film-forming. Alginate polymers isolated from different alginate sources vary in 
properties. Different algae, or for that matter different part of the same algae, yield 
alginate of different monomer composition and arrangement.  
 
The polymers with hydroxyl group require drastic conditions (low pH, 
high temperature, etc) in order to establish cross-linking with aldehydes, whereas 
amine containing polymers can be cross-linked with the same reagent under mild 
conditions where Schiff bases are formed.  
 
CHITOSAN 42 
Chitosan is a co polymer of D-glucosamine and N-acetyl glucosamine. 
Chitosan is a linear co polymer polysaccharide consisting of β (1–4)-linked 2-
amino-2-deoxy-D-glucose (D-glucosamine) and 2-acetamido-2-deoxy-D-glucose 
(N-acetyl-D-glucosamine) units in Figure 3. The structure of chitosan is very 
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similar to that of cellulose (made up of β (1–4)-linked D-glucose units), in which 
there are hydroxyl groups at C2 positions of the glucose rings. Chitosan is poly [β-
(1–4)-2-amino-2-deoxy-D-glucopyranose].  
 
The term chitosan is used to describe a series of polymers of different 
degrees of deacetylation (DD), defined in terms of the percentage of primary 
amino groups in the polymer backbone, and average molecular weights (Mw). 
The DD of typical commercial chitosan is usually between 70% and 95%, and the 
Mw between 10 and 1000 kDa. The properties, biodegradability and biological 
role of chitosan is frequently dependent on the relative proportions of N-acetyl-D-
glucosamine and D-glucosamine residues. 
 
 
Structure of chitosan 
 
 
Figure.3 
 
Alginate has the property of shrinking in low pH and getting dissolved in 
higher pH, whereas chitosan dissolves in low pH and is insoluble in higher pH 
ranges. In view of these limitations encountered in pure alginate and chitosan bead 
systems, the concept of alginate– chitosan complexes gained acceptance. The easy 
solubility of chitosan in low pH is prevented by the alginate network since 
alginate is insoluble in low pH conditions. The possible dissolution of alginate at 
higher pH is prevented by the chitosan which is stable at higher pH ranges. 
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Mechanism of cross-linking of Chitosan with formaldehyde 
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Among other biodegradable polymers, chitosan, a linear polysaccharide 
has been found to be a good chemical entity for synthesizing hydrogels because of 
its greater cross linking ability due to the presence of amino (–NH2) group. The 
biodegradability, biocompatibility and other unique properties of chitosan have 
been used in a variety of areas such as medicine, pharmaceutics, tissue 
engineering, antimicrobial agents as well as biomedical applications.  
 
GELATIN42 
 Gelatin is a fibrous protein that is produced from collagen and forms an 
aqueous gel. Gelatin gels are widely used in various fields of application, such as 
photography, pharmaceuticals, cosmetics and the food industry, because of the 
remarkable mechanical properties of gels and the natural biological origins of 
gelatin. In addition, gelatin is the most important wall material in the production 
of pharmaceutical micro-capsules that contain an active agent. 
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MECHANISM OF CROSS LINKING 
Although Ca2+ alginate beads can be prepared by simple and mild 
procedures, this method has a major limitation and that is the drug loss during 
bead preparation, by leaching through the pores in the beads. Therefore many 
modifications of alginate have been tested for the drug delivery purposes. Cross-
linking of alginate with aldehyde has been done successfully.  
 
Sodium alginate alone or gelatin has been cross-linked with aldehydes and 
their microparticles and beads have been prepared for various applications. Cross-
linked alginate has more capacity to retain the entrapped drugs and also it shows a 
more controlled release profile of entrapped drugs.  
 
It has been proposed that aldehyde groups can produce cross-linkage 
between alginate molecules through formation of bonds between two hydroxyl 
groups. 
 
The polymer having amino and/or hydroxyl group has ability to cross-
linked with formaldehyde to form network structure. Alginate, gelatin and 
chitosan are having the cross-linking functional group to cross-linked with 
aldehyde. The common reaction is given below. 
 
 
R NH2 + HCH - O -2 2 R
NH
NH
R
 
Figure.4 Mechanism of cross linking 
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MECHANISMS OF DRUG RELEASE FROM HYDROGEL BEADS13,30 
Hydrogel have a unique combination of characteristics that make them 
useful in drug delivery applications. Due to their hydrophilicity, hydrogels can 
imbibe large amounts of water. Therefore, the molecule release mechanisms from 
hydrogels are very different from hydrophobic polymers. Both simple and 
sophisticated models have been previously developed to predict the release of an 
active agent from a hydrogel device as a function of time. These models are based 
on the rate limiting step for controlled release and are therefore categorized as 
follows: 
1. Diffusion-controlled 
2. Swelling-controlled 
3. Chemically-controlled. 
1. Diffusion-controlled 
Diffusion-controlled is the most widely applicable mechanism for 
describing drug release from hydrogels. Fick's law of diffusion with either 
constant or variable diffusion coefficients is commonly used in modeling 
diffusion-controlled release. Drug diffusivities are generally determined 
empirically or estimated a priori using free volume, hydrodynamic, or obstruction-
based theories. 
 
2. Swelling-controlled 
Swelling-controlled release occurs when diffusion of drug is faster than 
hydrogel swelling. The modeling of this mechanism usually involves moving 
boundary conditions where molecules are released at the interface of rubbery and 
glassy phases of swollen hydrogels. The release of many small molecule drugs 
from hydroxypropyl methylcellulose (HPMC) hydrogel tablets is commonly 
modeled using this mechanism. For example, Methocel® matrices, a combination 
of methylcellulose and HPMC, from Dow Chemical Company are commercially 
available for preparing swelling-controlled drug delivery formulations exhibiting a 
broad range of delivery timescales. 
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3. Chemically-controlled 
 Chemically-controlled release is used to describe molecule release 
determined by reactions occurring within a delivery matrix. The most common 
reactions that occur within hydrogel delivery systems are cleavage of polymer 
chains via hydrolytic or enzymatic degradation or reversible or irreversible 
reactions occurring between the polymer network and releasable drug. Under 
certain conditions the surface or bulk erosion of hydrogels will control the rate of 
drug release. Alternatively, if drug-binding moieties are incorporated in the 
hydrogels, the binding equilibrium may determine the drug release rate. 
Chemically-controlled release can be further categorized according to the 
type of chemical reaction occurring during drug release. Generally, the liberation 
of encapsulated or tethered drugs can occur through the degradation of pendant 
chains or during surface erosion or bulk-degradation of the polymer backbone. A 
more thorough discussion of these mechanisms can be seen in a later section of 
this review as well as in several other excellent reviews. 
 
 
RHEUMATOID ARTHRITIS 8 ,9 ,55 ,26 
 
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that 
may affect many tissues and organs, but principally attacks synovial joints. The 
process produces an inflammatory response of the synovium (synovitis) secondary 
to hyperplasia of synovial cells, excess synovial fluid, and the development of 
pannus in the synovium. The pathology of the disease process often leads to the 
destruction of articular cartilage and ankylosis of the joints. Rheumatoid arthritis 
can also produce diffuse inflammation in the lungs, pericardium, pleura and 
sclera, and also nodular lesions, most common in subcutaneous tissue. Although 
the cause of rheumatoid arthritis is unknown, autoimmunity plays a pivotal role in 
both its chronicity and progression, and RA is considered a systemic autoimmune 
disease 
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Difference between Normal joint and joint affected by Rheumatoid Arthritis 
 
Figure.5 
 SIGNS AND SYMPTOMS  
While rheumatoid arthritis primarily affects joints, problems involving 
other organs of the body are known to occur. Extra-articular ("outside the joints") 
manifestations other than anemia (which is very common) are clinically evident in 
about 15–25% of individuals with rheumatoid arthritis. It can be difficult to 
determine whether disease manifestations are directly caused by the rheumatoid 
process itself, or from side effects of the medications commonly used to treat it – 
for example, lung fibrosis from methotrexate or osteoporosis from corticosteroids 
o Joints -With time RA nearly always affects multiple joints (it is a 
polyarthritis), most commonly small joints of the hands, feet and 
cervical spine, but larger joints like the shoulder and knee can also 
be involved. With time RA nearly always affects multiple joints (it 
is a polyarthritis), most commonly small joints of the hands, feet 
and cervical spine, but larger joints like the shoulder and knee can 
also be involved. 
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o  Skin- The rheumatoid nodule, which is often subcutaneous, is the 
cutaneous feature most characteristic of rheumatoid arthritis. The 
initial pathologic process in nodule formation is unknown but may 
be essentially the same as the synovitis, since similar structural 
features occur in both. The nodule has a central area of fibrinoid 
necrosis that may be fissured and which corresponds to the fibrin-
rich necrotic material found in and around an affected synovial 
space. Surrounding the necrosis is a layer of palisading 
macrophages and fibroblasts, corresponding to the intimal layer in 
synovium and a cuff of connective tissue containing clusters of 
lymphocytes and plasma cells, corresponding to the subintimal 
zone in synovitis 
Lungs 
Fibrosis of the lungs is a recognized response to rheumatoid disease. It is 
also a rare but well recognized consequence of therapy (for example with 
methotrexate and leflunomide). Caplan's syndrome describes lung nodules in 
individuals with rheumatoid arthritis and additional exposure to coal dust. Pleural 
effusions are also associated with rheumatoid arthritis. Another complication of 
RA is Rheumatoid Lung Disease. It is estimated that about one quarter of 
Americans with RA develop Rheumatoid Lung Disease.  
Kidneys 
Renal amyloidosis can occur as a consequence of chronic inflammation. 
Rheumatoid arthritis may affect the kidney glomerulus directly through a 
vasculopathy or a mesangial infiltrate but this is less well documented. 
Heart and Blood Vessels 
•  atherosclerosis  
• risk of myocardial infarction (heart attack)  
•  stroke  
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•  pericarditis 
•  endocarditis 
•  left ventricular failure 
• valvulitis  
•  fibrosis  
DIAGNOSIS 
 
Imaging 
 X-rays of the hands and feet are generally performed in people with a 
polyarthritis. In rheumatoid arthritis, there may be no changes in the early stages 
of the disease, or the x-ray may demonstrate juxta-articular osteopenia, soft tissue 
swelling and loss of joint space. As the disease advances, there may be bony 
erosions and subluxation. X-rays of other joints may be taken if symptoms of pain 
or swelling occur in those joints.Other medical imaging techniques such as 
magnetic resonance imaging (MRI) and ultrasound are also used in rheumatoid 
arthritis.  
Blood Test 
When RA is clinically suspected, immunological studies are required, such 
as testing for the presence of rheumatoid factor (RF, a non-specific antibody). A 
negative RF does not rule out RA. The arthritis is called seronegative. This is the 
case in about 15% of patients. During the first year of illness, rheumatoid factor is 
more likely to be negative with some individuals converting to seropositive status 
over time. RF is also seen in other illnesses, for example Hepatitis C, chronic 
infections and in approximately 10% of the healthy population, therefore the test 
is not very specific. 
Also, several other blood tests are usually done to allow for other causes of 
arthritis, such as lupus erythematosus. The erythrocyte sedimentation rate (ESR), 
C-reactive protein, full blood count, renal function, liver enzymes and other 
immunological tests (e.g., antinuclear antibody/ANA) are all performed at this 
stage. 
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DIFFERENTIAL DIAGNOSIS 
Several other medical conditions can resemble RA, and usually need to be 
distinguished from it at the time of diagnosis 
¾ Crystal induced arthritis (gout, and pseudogout) – usually involves 
particular joints (knee, heels) and can be distinguished with aspiration of 
joint fluid if in doubt. Redness (RA doesn't have redness at the joints), a-
symetric distibution of affected joints, pain occurs at night and the starting 
pain is less than an hour with gout. 
¾ Osteoarthritis – distinguished with X-rays of the affected joints and blood 
tests, age (mostly older patients), starting pain less than an hour, a-
symetric distribution of affected joints and pain worsens when using joint 
for longer periods. 
¾ Systemic lupus erythematosus (SLE) – distinguished by specific clinical 
symptoms and blood tests (antibodies against double-stranded DNA) 
¾ One of the several types of psoriatic arthritis resembles RA – nail changes 
and skin symptoms distinguish between them 
¾ Lyme disease causes erosive arthritis and may closely resemble RA – it 
may be distinguished by blood test in endemic areas 
¾ Reactive arthritis (previously Reiter's disease) – asymmetrically involves 
heel, sacroiliac joints, and large joints of the leg. It is usually associated 
with urethritis, conjunctivitis, iritis, painless buccal ulcers, and 
keratoderma blennorrhagica. 
¾ Ankylosing spondylitis – this involves the spine and is usually diagnosed 
in males, although a RA-like symmetrical small-joint polyarthritis may 
occur in the context of this condition. 
¾ Hepatitis C – RA-like symmetrical small-joint polyarthritis may occur in 
the context of this condition. Hepatitis C may also induce Rheumatoid 
Factor auto-antibodies 
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PATHOPHYSIOLOGY 
Rheumatoid arthritis is best considered a clinical syndrome spanning 
several disease subsets. These different subsets entail several inflammatory 
cascades which all lead towards a final common pathway in which persistent 
synovial inflammation and associated damage to articular cartilage and underlying 
bone are present. 
 
Inflammation 
One key inflammatory cascade includes overproduction and over 
expression of TNF. This pathway drives both synovial inflammation and joint 
destruction. TNF overproduction has several causes, including interactions 
between T and B lymphocytes, synovial-like fibroblasts, and macrophages. This 
process leads to overproduction of many cytokines such as interleukin, which also 
drives persistent inflammation and joint destruction. Overproduction of other 
proinflammatory cytokines (eg, interleukin-1) differs from the process for 
interleukin 6 in that production is either less marked or is specific to one or more 
disease subsets, as best shown by the effects of interleukin-1 blockade in subforms 
of juvenile idiopathic arthritis or adult-onset Still’s disease.  
 
Synovial cells and cartilage cells 
The dominant local cell populations in joints affected by rheumatoid 
arthritis are synovial and cartilage cells. Synovial cells can be divided into 
fibroblast-like and macrophage-like synoviocytes. Overproduction of 
proinflammatory cytokines is believed to be led predominantly by macrophage-
like synoviocytes. Fibroblast-like synoviocytes show abnormal behavior in 
rheumatoid arthritis. In experimental models, co-implantation of fibroblast-like 
synoviocytes with cartilage leads to fibroblasts invading cartilage, behaviour that 
correlates with joint destruction. Considerable information has accumulated about 
joint destruction and the role of osteoclast activation as a key process leading to 
bone erosion. This association is proven because specific inhibition of osteoclast 
activation can reduce joint destruction yet not affect joint inflammation. We are 
unclear about whether arthritis starts as a primary problem in the bone and 
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subsequently moves to the joint, or the other way around. One argument for 
rheumatoid arthritis starting in the joint is the observation that fibroblast-like 
synoviocytes showing altered behaviour can spread between joints, suggesting 
how polyarthritis might develop. 
 
Regulation of immune inflammation depends on balances between the 
number and strength of different cell types. Control of arthritogenic 
immunoresponses has been studied in mice in which the specific antigen is 
known. Infusion of low numbers of T cells with specific characteristics 
ameliorates arthritis in a rodent model of the disease, showing T cells can be 
protective. Ongoing research should translate these experimental findings into 
clinical practice. 
 
Autoantibodies 
Rheumatoid factor is the classic autoantibody in rheumatoid arthritis. IgM 
and IgA rheumatoid factors are key pathogenic markers directed against the Fc 
fragment of IgG. Additional (and increasingly important) types of antibodies are 
those directed against citrullinated peptides (ACPA). Although most, but not all, 
ACPA-positive patients are also positive for rheumatoid factor, ACPA seem more 
specific and sensitive for diagnosis and seem to be better predictors of poor 
prognostic features such as progressive joint destruction.  
Ongoing research aims to identify antibody specificities relevant for 
different patients’ subsets and disease stages. 50–80% of individuals with 
rheumatoid arthritis have rheumatoid factor, ACPA, or both. Composition of the 
antibody response varies over time, with limited specificities in early rheumatoid 
arthritis and a mature response, in which more epitopes are recognised and more 
isotypes used in late disease.  
Evidence from animal models and in-vivo data suggest that ACPA are 
pathogenic on the basis of induction of arthritis in rodent models and because 
immunological responses are present in ACPA-positive patients in a citrulline-
specific manner. Findings of clinical studies show that patients with rheumatoid 
arthritis and both rheumatoid factor and ACPA (autoantibody-positive disease) 
differ from individuals with so-called autoantibody-negative disease.  
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For example, histologically, people with ACPA-positive disease have 
more lymphocytes in synovial tissue, whereas those with ACPA-negative 
rheumatoid arthritis have more fibrosis and increased thickness of the synovial 
lining layer. ACPA-positive disease is associated with increased joint damage and 
low remission rates. 
 
Genetics 
50% of risk of developing rheumatoid arthritis is attributable to genetic 
factors. Much progress has been made in identification of genetic regions tagged 
by structural variation (single nucleotide polymorphisms); more than 30 genetic 
regions are associated with rheumatoid arthritis.  
 
CLASSIFICATION AND DIAGNOSIS 
Early classification criteria were designed to distinguish established 
rheumatoid arthritis from other types of established joint diseases. They ensured 
researchers studied homogeneous patients’ groups, particularly in clinical trials. 
 
CLASSIFICATION OF EARLY ARTHRITIS  
The American College of Rheumatology (ACR) 1987 criteria are limited 
by poor sensitivity and specificity for classification of patients with early 
inflammatory arthritis as having rheumatoid arthritis. They fail to identify 
individuals with very early arthritis who subsequently develop rheumatoid 
arthritis.  
Effective treatment in early arthritis averts or delays patients fulfilling 
these 1987 criteria, and two criteria-erosive joint damage and extra-articular 
disease are late changes prevented by modern treatment. Prediction models have 
been developed from prospective observational studies of treated patients with 
early arthritis. These models are designed to forecast outcomes in individuals with 
early arthritis who do not currently meet the 1987 criteria.  
Several factors can establish whether patients are likely to develop 
rheumatoid arthritis. In the presence of inflammatory arthritis, evidence of 
systemic inflammation shown by high acute-phase reactants and prolonged 
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morning stiffness and autoantibodies in serum, particularly ACPA and rheumatoid 
factor increases the likelihood of individuals having rheumatoid arthritis. 
 
EPIDEMIOLOGY 
 
Frequency 
Findings of population-based studies show rheumatoid arthritis affects 
0·5–1·0% of adults in developed countries. The disease is three times more 
frequent in women than men. Prevalence rises with age and is highest in women 
older than 65 years, suggesting hormonal factors could have a pathogenic role. 
Estimates of the frequency of rheumatoid arthritis vary depending on the methods 
used to ascertain its presence. Incidence ranges from 5 to 50 per 100 000 adults in 
developed countries and increases with age.  
 
Prevalence of rheumatoid arthritis varies geographically. The disease is 
common in northern Europe and North America compared with parts of the 
developing world, such as rural West Africa. These variations are indicative of 
different genetic risks and environmental exposures. Some evidence suggests 
incidence of rheumatoid arthritis might be declining, with onset happening later in 
life. 
 
Environmental risk factors 
 
Smoking is the dominant environmental risk factor and doubles risk of 
developing rheumatoid arthritis. Its effect is restricted to patients with ACPA-
positive disease. Although pathogenetically very important, on a population level, 
the risk is too low to be clinically relevant. Other potential environmental risk 
factors include alcohol intake, coffee intake, vitamin D status, oral contraceptive 
use, and low socioeconomic status, although supporting evidence for these other 
factors is weak. 
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LITERATURE REVIEW 
Dilipkumar Pal et al., 201210 developed multiple-unit alginate based floating 
system for delivery o cloxacillin. Bead size ranged from 1.73 ± 0.04 to 1.97 ± 0.08 
mm. Increasing bead size was found to be increasing the sodium alginate 
concentration. Liquid paraffin entrapped calcium alginate beads containing 
cloxacillin was observed with increasing of polymer content and decreasing of 
liquid content in the beads. The diffusion mechanism of drug release demonstrate 
both diffusion controlled as well as swelling controlled from beads. 
 
Mradul R. Gupta et al., 201011 reviewed alginate/chitosan particulate system for 
Diclofenac sodium release by ionic gelation technique (Ca2+ and Al3+). The 
release of sodium diclofenac was prevented at acidic pH, while it was complete in 
a few minutes when pH was raised up to 6.4 and 7.2. The alginate/chitosan ratio 
and the nature of the jellifying cation controlled the release rate of the drug. 
 
Santanu Chakraborty et al., 201012 formulated micro-particulate drug delivery 
of poorly water soluble drug Aceclofenac using alginate-carbopol as a rate 
controlling polymer was able to restrict the drug release in stomach. Formulation 
was able to release drug upto 12 hour and follow the anomalous non-fickian 
diffusion mechanism. 
 
Miqin Zhang et al., 201013 reviewed that application of chitosan in hydrogel for 
controlled and localized drug delivery. Method of drug loading into hydrogel such 
as direct addition of drug, incorporation of separate release system, covalent 
attachment and method of cross linking and formulation of hydrogel beads were 
given. Importantly, how the unique cationic properties of chitosan offer greater 
latitude in the types of hydrogels that can be formed and the mechanisms by 
which they fragment and degrade in the body. 
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Girhepunje K M et al., 201014 prepared microbead formulations of celecoxib 
inclusion complex using sodium alginate and Eudragit FS 30‐D as a carrier for 
colonic administration to extend the retention of the drug in order to treat 
colorectal cancer. Coated celecoxib microbeads (1:1ratio) showed cytotoxicity 
against HT‐29 cells. DNA Fragmentation study confirms the better anti cancer 
activity of celecoxib microbeads against human colorectal adenocarcinoma cell 
line HT‐29. Hence the formulations can be effectively tested for its anticancer 
activity. 
 
Patel H K et al., 201015 prepared and evaluated the colon-specific alginate beads 
of 5-Fluorouracil for the treatment of colon cancer. The core beads were coated 
with Eudragit S-100 to prevent drug release in the stomach and provide controlled 
dissolution of enteric coat in the small intestine and maximum drug release in the 
colon. No significant release was observed at acidic pH, however, when it reached 
the pH where Eudragit S-100 starts to dissolve, drug release was observed. Also, 
release of drug was found to be higher in presence of rat caecal content. 
 
Senthil kumaran K et al., 201016 formulated mosapride-controlled release beads 
were prepared with the help of the ionotropic gelation method, using sodium 
alginate containing KHCO3 as the gas-forming agent. The percentage of 
mosapride drug entrapment efficiency ranged from 97.4± 0.08 to 99.1 ± 0.04%. 
The percentage of mosapride content from the beads was determined by high 
performance liquid chromatography (HPLC) and ranged from 97.9 ± 0.08 to 
99.6% ± 0.01. The in-vitro release study was carried out for 14 hours and the 
formulate beads were kept for stability studies for 90 days at 40°C / 75% RH. 
 
Badarinath A V et al., 201017 formulated Flurbiprofen microbeads by varying the 
alginate, CaCl2 and HPMC concentrations. Prepared beads were evaluated for 
granulometric studies, micromeretic, scanning electron microscopy, drug 
entrapment efficiency and in-vitro dissolution studies etc. The prepared beads 
were free flowing and white in color. The drug loaded beads showed 83.6 – 98.2 
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% drug entrapment, which was found to increase with increase in sodium alginate 
concentration. Scanning electron microscopy revealed that the beads were 
spherical and rough in structure. In-vitro drug release study of these microbeads 
indicated controlled release for flurbiprofen 84.54 – 97.74 % release at the end of 
10 hour. 
 
Baljit Singh et al 201018 reported that Gastroretentive floating sterculia–alginate 
beads for use in antiulcer drug delivery by using aldehyde as cross-linking agent. 
 
C. Kumaresan 201019 reported that Dexibuprofen is the superior non steroidal 
anti-inflammatory agents for development of pharmaceuticals. The racemic 
mixture of S (+) Ibuprofen and R (‐) Ibuprofen being used, but the biological 
activity is mainly due to S (+) Ibuprofen. The development of dosage forms with 
ibuprofen involves major problem to achieve bioavailability and stability. 
Enantiomers have same physical and chemical properties. But differ in 
three‐dimensional spatial arrangement. This leads to difference in 
pharmacodynamics and pharmacokinetics. The differences often depend on 
whether the center of asymmetry of the drug is in close proximity to the points of 
attachment to the protein. S (+) Ibuprofen is over 100‐fold more potent an 
inhibitor of cyclooxygenase‐ I than R‐Ibuprofen. 
 
Alam M I et al., 201020 prepared various formulations of mucoadhesive beads of 
gliclazide using two different natural polymers, alginate and ispaghula, in various 
stoichiometric proportions with CaCl2 as a source of counter ions and they were 
characterized for entrapment efficiency, particle size, surface morphology, and 
swelling index. The kinetics of drug release and their mucoadhesive nature in 
vitro using goat intestinal mucosa was also investigated at various physiological 
pH conditions. The effective mucoadhesion property with sustained release profile 
was observed from optimized mucoadhesive beads consisting of alginate and 
ispaghula husk (1:1) and polymer (2:1) with 5–10% w/v counter ions (CaCl2). 
These formulations showed optimum mucoadhesion behavior having more than 
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70% w/v of drug entrapment and particle sizes of 896.7±0.8 and 920.6±1.2µm, 
respectively. 
 
Sridhar B K et al., 201021 prepared alginate and chitosan beads of theophylline 
by ionotropic gelation method followed by enteric coating with Eudragit S100.All 
formulations were evaluated for particle size, encapsulation efficiency, 
swellability and in vitro drug release. The drug release from coated beads depends 
on coat weights applied and pH of dissolution media. Mechanism of drug release 
was found to be swelling and erosion-dependent. The studies showed that 
formulated alginate and chitosan beads can be used effectively for the delivery of 
drug to colon and a coat weight of 20% weight gain was sufficient to impart an 
excellent gastro resistant property to the beads for effective release of drug at 
higher pH values. 
 
Manjanna K M et al., 200922 developed sustained release dexibuprofen 
microbeads using sodium alginate as the hydrophilic carrier in combination with 
Guar gum, Chitosan and pectin as coated polymers to modify the drug release. 
Microbeads prepared only with sodium alginate show faster drug release. To 
overcome such inconveniences, polymer-coated alginate microbeads and/or 
appropriately interpenetrating polymer network structures formed with alginate 
and other macromolecules were developed. Microbeads coated with chitosan and 
guar gum aqueous polymer dispersion shows optimum level of sustained release 
and exhibited zero-order kinetics followed by super case-II transport. 
 
Sanap Gajanan S et al., 200923 formulated mucoadhesive beads of glipizide 
employing sodium alginate, carbopol 974P and Sodium Carboxy Methyl 
Cellulose(SCMC). The prepared formulations were evaluated for physical 
parameter, mucoadhesive properties, in-vitro wash-off test, in-vitro drug release 
and in-vivo test.  
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Sachan N K et al., 200924 prepared hydrogel microbeads of metformin by 
ionotropic gelation method using the blends of pre-gelatinized Bora rice along 
with sodium alginate as mucoadhesive backbone. The drug entrapment efficiency 
was initially very low for the metformin hydrochloride because it is being highly 
water soluble, diffuses out to calcium chloride solution at the time of 
encapsulation or during curring. This was improved considerably by some 
changes in encapsulation process as the drug was thoroughly mixed with pre-
gelatinized starch gel to get it to penetrate to the hollow hilum of rice granule that 
hinders diffusion. 
 
Patel V A et al ., 200925 developed the chitosan beads containing methotrexate by 
using ionotropic gelation method by dropping methotrexate containing solution of 
positively charged chitosan into tri poly phosphate solution. It was observed that 
beads containing higher proportion of span 80 showed faster release and the beads 
with the higher proportion of TPP showed delayed release. Drug release kinetics 
from these formulations corresponds best to the first order kinetics. 
 
Manjanna K M et al., 200926 formulated diclofenac microbeads by using sodium 
alginate alone and combination with coating polymers like HPMC, chitosan, 
pectin and calcium chloride used as cross linker. The drug entrapment efficiency 
increased progressively with increasing concentration of both sodium alginate and 
coating polymer resulting in the formation of larger microbeads entrapping greater 
amounts of the drug. Increase in concentration of sodium alginate tends to make 
particle more spherical. Increase in concentration of calcium chloride significantly 
affects the mean diameter but no appreciable change in morphology and release 
behavior. 
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Srinatha A et al., 200827 studied chitosan beads loaded with ciproflaxin 
hydrochloride were fabricated by ionic cross linking with sodium tri poly 
phosphate. The beads showed excellent water retention property. Drug release was 
higher in acidic medium (pH 1.2) vis- a vis intestinal medium (pH 7.4) ciproflaxin 
hydrochloride release increased with an increasing concentration of ciproflaxin 
and decrease in the proportion of chitosan. Drug release followed both first order 
and Higuchi’s root time kinetics showing Non- Fickian release mechanism. 
 
24Frances Stops et al., 200828 developed Floating calcium alginate beads for the 
delivery of Riboflavin with citric acid. SEM confirmed spherical structure of 
beads. Citric acid increase rate of drug release from alginate beads was slowest in 
acidic medium pH 1.2 and quickest in more alkaline medium. The release of 
Riboflavin from the calcium alginate beads complete within 6 hours. Furthermore 
modifications are required to alter the rate of drug release from floating calcium 
beads. 
 
Sanjay K. Jain et al 200737 developed multiparticulate system of chitosan 
hydrogel beads by aldehyde a cross linker for colon targeted delivery of 
satranidazol chitosan hydrogel beads coated with Eudragit S100 having size upto 
1.95±0.05mm. The drug released after 24 hours was found to be 97.67% ± 1.25%. 
Degradation of the chitosan hydrogel beads in the presence of extracellular 
enzymes indicate the potential of the microparticulate system to serve as a carrier 
to deliver the molecules specifically to the colon. 
 
18Andrew T. Metters et al., 200630 reported hydrogel have been a vital role in the 
biomedical field with increasing efforts devoted to sustained release will continue 
in  future due to need of sustained action of drug. Further more advanced release 
system would be developed such as affinity hydrogel microparticle system and in 
situ forming gel. Proper network design and accurate mathematical modeling are 
keys to tuning the drug release rates. 
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Emilia Abraham T et al., 200631 reported that Chitosan–alginate complexes as a 
pH sensitive hydrogel have been studied for the development of oral delivery. 
Alginate has the property of shrinking in low pH and getting dissolved in higher 
pH, whereas chitosan dissolves in low pH and is insoluble in higher pH ranges. 
Complexation of chitosan with alginate reduces the porosity of alginate beads and 
decreases the leakage of the encapsulated drugs.  
 
Almeida A.J. et al, 200432 reported alginate-gelatin beads cross linked by 
aldehyde (formaldehyde or glutaraldehyde) as cross-linking agent to formulate a 
new matrix for controlled release of pindolol. All formulations were evaluated for 
particle size, encapsulation efficiency, gelling rate, swelling rate and in-vitro drug 
release studies. Gelling rate indicates the speed and degree of polymer reaction on 
the formation of reticulated structure. Swelling studies indicates speed and 
easiness of a liquid to penetrate the alginate-gelatin matrix. Also,cross-linking 
agent delays drug release from beads. Polymer such as Eudragit (RD100, RL30D, 
RS30D), Carbopol or Ethylcellulose, did not improve the matrix ability to prolong 
drug release.  
 
Tejraj M. Aminabhavi et al., 200433 reported chitosan bead containing clozapin 
microparticle with glutaraldehyde as cross linker showed high entrapment efficacy 
of upto 98.97% and release upto 12 hours. In-vivo Albino rate absortion of drug 
was delayed from microparticles. Since AUC was higher when compared to neat 
clozapin. In-vivo studies indicated the absorption pattern of clozapin of from 
microparticle were in a controlled manner. 
 
Mansoor Amiji et al., 200334 reported that physical, chemical and biological 
properties make chitosan a good candidate for the development of Novel 
gastrointestinal drug delivery system such as stomach specific drug delivery, 
intestinal drug delivery and colon specific drug delivery. Drug targeting with 
chitosan was illustrated by in vivo animal model revealed that chitosan is a good 
candidate for gastrointestinal drug delivery. 
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Bonabello et al., 200335 studied the anti-inflammatory and analgesic effect of 
Dexibuprofen and ibuprofen in rodents. From the animal studies in rats, S(+) 
ibuprofen isomer was found to be more potent than the racemic formulation in 
analgesic and anti-inflammatory activities. From IV dose, both drug 
(Dexibuprofen and Ibuprofen) showed significant analgesic effect. But ED50 of 
dexibuprofen was half of effective dose of Ibuprofen. From peroral 
administration, the ED50 of Dexibuprofen was less when compared to ED50 of 
Ibuprofen. Showed that dexibuprofen have better analgesic and anti-inflammatory 
effect than racemic ibuprofen. 
 
Gonzalez-Rodriguez M.L et al., 200236 reported Alginate/chitosan particulate 
systems for sodium Diclofenac release with Al3+ and Ca2+.The release from the 
beads was examined as a function of pH of the dissolution medium indicated that 
drug release was prevented in acidic pH. Alginate microspheres containing 
diclofenac start to release the drug after the pH of the environment increases 
above 7. Alginate/chitosan ratio and the nature of the jellifying cation allow a 
control of the release rate of the drug. 
 
Mitsutoshi Nakajima et al 200250 developed a new technique for gelatin (Type 
B) microbeads with narrow size distribution by using microchannel emulsification 
for W/O and O/W emulsion. 
 
Tejraj M. Aminabhavi et al., 200038 reported Glutaraldehyde cross-linked 
sodium alginate beads containing liquid pesticide for soil application. The absence 
of chemical interactions between active ingredients and polymer as well as cross-
linking agent was confirmed by FTIR spectral measurements. The SEM data 
indicated that the structure of the walls of the beads are smooth and nonporous. 
From ‘n’ value, indicating that diffusion deviate slightly from Fickian transport. 
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John T. Fell et al., 200039 formulated alginate beads by varying the alginate using 
CaCl2 as a counter ion. Prepared beads were evaluated. Drug release studies 
showed that beads prepared with the drug in solution provided some sustained 
release characteristics and these could be improved by the addition of amylose. 
Scanning electron microscopy revealed that the beads were almost spherical in 
shape. In-vitro drug release study of these beads indicated sustained release for 
amoxycillin. 
 
Tejraj M. Aminabhavi et al., 199940 designed sodium alginate containing 
diclofenac sodium by the precipitation of alcohol followed by glutaraldehyde as a 
cross linker in acidic medium. Entrapment efficacy depends upon the preparation. 
SEM indicates non-porous surface of beads. The particle size was not varied 
either by increasing exposure time to cross link or by increasing percentage 
loading of active ingredient. The beads exposed to long time to glutaraldehyde 
required long time to dry when compared to beads exposed to lesser time to 
glutaraldehyde. 
 
Fernandez-Hervas M.J et al., 199837 developed diclofenac beads from sodium 
alginate, chitosan and /or Eudragit L30D by CaCl2 as cross-linking agent for the 
delivery of practically insoluble drug diclofenac salt into the small intestine. High 
entrapment efficacy was obtained with chitosan having the range of 91.26% to 
95.99%. Release depends upon the pH.SEM shows Spherical nature of beads after 
drying in room temperature. At low pH, the non swelling should reduce the matrix 
permeability and limit the drug diffusion. 
 
Kinam Park et al., 199341 reported biodegradable hydrogels have been exploited 
in the controlled drug delivery area due to various advantages. Biodegradable 
hydrogel can possess other properties like bioadhesive, pH-sensitive, temperature-
sensitive or other environmental sensitive properties. These properties have been 
used to design the sustained release drug delivery. 
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AIM AND OBJECTIVE  
The aim of the present study is to formulate and evaluate the sustained 
release of cross-linked hydrogel dexibuprofen beads by using formaldehyde as a 
cross linking agent with different ratio of polymer like sodium alginate, chitosan 
and gelatin.  
Dexibuprofen [S (+)-ibuprofen], pharmacologically active enantiomer of 
racemic ibuprofen, is a non-steroidal substance with anti-inflammatory and 
analgesic effects. That is absorbed primarily from the small intestine. But it 
undergoes a significant first pass metabolism which may reduce the systemic 
bioavailability of Dexibuprofen. After metabolic transformation in the liver, the 
pharmacologically inactive metabolites are completely excreted, mainly by the 
kidneys (90%), but also in the bile. The elimination half- life is 1.8-3.5 hours.  
 
Oral ingestion is the traditionally preferred route of drug administration, 
providing a convenient method of effectively achieving both local and systemic 
effect. In conventional oral drug delivery systems, there is very little control over 
release of the drug. The effective concentration can be achieved by intermittent 
administration of excessive doses, which, in most situations, often results in 
constantly changing, unpredictable, and often sub- or supra-therapeutic plasma 
concentrations leading to marked side effects. 
 
 An ideal oral drug delivery system should steadily deliver a measurable 
and reproducible amount of drug to the site over a prolonged period. Sustained 
release (SR) delivery systems provide a uniform concentration/amount of the drug 
at the absorption site and thus, after absorption, allow maintenance of plasma 
concentrations within a therapeutic range, which minimizes side effects and also 
reduces the frequency of administration.SR products are formulations that release 
active drug compounds into the body gradually and predictably over a long period 
and that can be taken once a day. Typically, these products provide numerous 
benefits compared with immediate release drugs, including greater effectiveness 
in the treatment of chronic conditions, reduced side effects, greater convenience, 
and higher levels of patient compliance due to a simplified dosing schedule.  
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PLAN OF WORK 
¾ Collection of drug and Polymer 
¾ Preformulation studies 
a. Description 
b. Solubility 
c. Identification of the drug 
• UV absorption maxima 
• FT-IR Studies 
d. Drug-Excipient Compatibility studies by FTIR 
¾ Formulation of Hydrogel Beads 
¾ Evaluation parameters 
 
• Gelling rate  
• Particle size by Optical Microscopy 
• Shape and Surface morphology by Scanning Electron 
Microscopy  
• Drug Content Analysis and Percentage Drug Entrapment  
• In-vitro release profile  
• Swelling studies  
 
¾ Release kinetics 
¾ Stability testing  
¾ Results and discussion 
¾ Conclusion 
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DRUG PROFILE20, 42, 59, 60 
Drug Name   :  Dexibuprofen 
IUPAC Name   :  (2S)-2-[4-(2-methylpropyl) phenyl] propanoic acid 
Molecular Structure  : 
 
 
 
 
 
 
 
 
 
Figure.6 
 
Molecular formula  :  C13H18O2 
Molecular weight  :  206.280 g/mol 
Metabolism   :  Liver 
Mode of action  :  Inhibition of cyclooxygenase 
Elimination Half Life :  1.8-3.5hours 
Protein binding  :  About 99% 
t max    :  About 2 hour 
Dose    : 1200mg/day (Maximum) 
Excretion   :  Mainly by renal 
Use    :  Arthritis 
Storage   :  Store at 25ºC or below 
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MECHANISM OF ACTION8 
Major mechanism of Dexibuprofen is inhibition of PG genenation. 
Prostaglandins, prostacyclin(PG I2) and thrombaxane A2 are produced from 
arachidonic acid by the enzyme cyclooxegenase. Which exists in a constitutive 
(COX-1) and an inducible (COX-2) isoforms; former servers physiological ‘house 
keeping’ funtion, while the latter,normally present in minute quantities, is induced 
by cytokines and other signal molecules at the site of inflammation. Which cause 
the generation of PGs locally which mediate many of the inflammatory changes. 
 
Mechanism of action 
 
Figure.7 
 
Therapeutic Indications 
 
¾ Symptomatic treatment for the relief of pain and inflammation 
associated with osteoarthritis.  
¾ Acute symptomatic treatment of pain during menstrual bleeding 
(primary dysmenorrhoea).  
¾ Symptomatic treatment of other forms of mild to moderate pain, such 
as muscular-skeletal pain or dental pain Contraindications 
 
¾ Patients previously sensitive to dexibuprofen, to any other NSAID 
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¾ Patients in whom substances with a similar action (e.g. aspirin or other 
NSAIDs) precipitate attacks of asthma, bronchospasm, acute rhinitis, 
or cause nasal polyps, urticaria or angioneurotic oedema.  
¾ Patients with active or suspected gastrointestinal ulcer or history of 
recurrent Gastrointestinal  ulcer.  
¾ Patients with active Crohn's disease or active ulcerative colitis.  
¾ Patients with severe heart failure.  
¾ Patients with severe renal dysfunction (GFR < 30ml/min).  
¾ Patients with severely impaired hepatic function.  
¾ Patients with haemorrhagic diathesis and other coagulation disorders, 
or patients receiving anticoagulant therapy.  
¾ Patients who have gastrointestinal bleeding or other active bleedings or 
bleeding disorders. 
 
Drug interaction 
 
 In general, NSAIDs should be used with caution with other drugs that can 
increase the risk of gastrointestinal ulceration or gastrointestinal bleeding or renal 
impairment.  
¾ Acetylsalicylic acid 
¾ Antihypertensives 
¾ Cyclosporin, tacrolimus 
¾ Corticosteroids 
¾ Digoxin 
¾ Methotrexate  
¾ Phenytoin 
¾ Thiazides, thiazide-related substances, loop diuretics and potassium-
sparing diuretics. 
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Posology 
For individual dosage film-coated tablets with 200, 300 and 400 mg 
dexibuprofen are available. The recommended dosage is 600 to 900 mg 
dexibuprofen daily, divided in up to three single doses. For the treatment of mild 
to moderate pain, initially single doses of 200 mg dexibuprofen and daily doses of 
600 mg dexibuprofen are recommended.  
 
The maximum single dose is 400 mg dexibuprofen. The dose may be 
temporarily increased up to 1200 mg dexibuprofen per day in patients with acute 
conditions or exacerbations. The maximum daily dose is 1200 mg. For 
dysmenorrhoea a daily dose of 600 to 900 mg dexibuprofen, divided in up to three 
single doses, is recommended. The maximum single dose is 300 mg, the 
maximum daily dose is 900 mg.  
 
Dexibuprofen has not been studied in children and adolescents (< 18 
years). Safety and efficacy have not been established and therefore it is not 
recommended in these age groups. In general NSAIDs (non-steroidal anti-
inflammatory drugs) are preferably taken with food to reduce gastrointestinal 
irritation, particularly during chronic use. However, a later onset of action in some 
patients may be anticipated when the tablets are taken with or directly after a 
meal. 
 
Precautions 
Precautions are taken for symptoms or history of gastro-intestinal disease, 
asthma, impaired hepatic, cardiac or renal function. NSAID may mask infections 
or temporarily inhibit platelet aggregation. In late pregnancy, as with other 
NSAIDs, it should be voided as it may cause premature closure of ductus 
arteriosus. Dexibuprofen should be used with caution in nursing mothers. 
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Special Warnings and Precautions 
¾ Care is recommended in conditions that predispose patients to the 
gastrointestinal adverse effects of NSAIDs such as dexibuprofen, 
including existing gastrointestinal disorders, previous gastric or duodenal 
ulcer, ulcerative colitis, Crohn's disease and alcoholism.  
¾ Gastrointestinal bleeding or ulceration/perforation have in general more 
serious consequences in the elderly. They can occur at any time during 
treatment with or without warning symptoms or a previous history of 
serious gastrointestinal events.  
¾ In the treatment of patients with heart failure, hypertension, renal or 
hepatic disease, especially during concomitant diuretic treatment, the risk 
of fluid retention and a deterioration in renal function must be taken into 
account. If used in these patients, the dose of dexibuprofen should be kept 
as low as possible and renal function should be regularly monitored.  
¾ Caution is required in patients suffering from, or with a previous history of 
bronchial asthma since NSAIDs can cause bronchospasm in such patients. 
¾ In common with other NSAIDs dexibuprofen may reversibly inhibit 
platelet aggregation and function and prolong bleeding time. Caution 
should be exercised when dexibuprofen is given concurrently with oral 
anticoagulants. 
 
Pregnancy 
Inhibition of prostaglandin synthesis may adversely affect the pregnancy 
and/or the embryo/fetal development, and as the consequences of inhibiting the 
synthesis of prostaglandins are not fully known, dexibuprofen, like other drugs of 
this class, should only be administered in the first 5 months of pregnancy if clearly 
needed, in the lowest effective dose and as short as possible. During the third 
trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus 
to 
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¾ Cardiopulmonary toxicity  
¾ Renal dysfunction  
¾ Possible prolongation of bleeding time,  
¾ Inhibition of uterine contractions resulting in delayed or prolonged labour.  
The use of dexibuprofen, as with any drug substance known to inhibit 
cyclooxygenase / prostaglandin synthesis is not recommended in women 
attempting to conceive. 
 
Lactation 
Ibuprofen is slightly excreted in human milk. Breast-feeding is possible 
with dexibuprofen if dosage is low and the treatment period is short.  
Concomitant use not recommended:  
¾ Anticoagulants 
¾ Methotrexate 
¾ Lithium 
¾ Other NSAIDs and Salicylates 
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EXCIPIENTS PROFILE4 
SODIUM ALGINATE 
 Sodium alginate consists chiefly of the sodium salt of alginic acid, which 
is a mixture of polyuronic acids composed of residues of D-mannuronic acid and 
L-guluronic acid.  
 
Empirical formula: (C6H706Na)n 
Chemical structure: 
 
Figure.8  
Solubility 
It is slowly soluble in water and forming a viscous colloidal solution. It is 
insoluble in alcohol & hydro alcoholic solution. It is insoluble in other organic 
solvents and aqueous acidic solutions in which the pH of the resulting solution is 
less than 3.0. 
Viscosity  
¾  1% w/v aqueous solution should be 20-400 cps at 20°C 
pH : ~ 7.2 
Description 
It occurs as odorless and tasteless, white to pale yellowish-brown colored 
powder. 
Safety 
 Sodium alginate is regarded as a non-toxic and non-irritant material. 
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Incompatibility 
It is incompatible with crystal violet, acridine derivatives, phenyl mercuric 
nitrate and acetate, ethanol, calcium salts in concentration greater than 5% and 
heavy metals. 
 
Application 
Used as a stabilizer in emulsions as a suspending agent and tablet binder. 
sodium alginate has been used in combination with an H2-receptor antagonist in 
the management of gastro esophageal reflux. It is also used as a haemostatic agent 
in surgical dressing. 
 
GELATINE 
Nonproprietary Names: 
BP  :  Gelatin 
JP  :  Gelatin 
PhEur  :  Gelatina 
USPNF :  Gelatin 
 
Synonyms 
Byco, Cryogel, Gelatine, Instagel, Solugel. 
 
Emperical formula 
 Gelatin is a generic term for a mixture of purified protein fractions 
obtained either by partial acid hydrolysis (type A gelatin) or by partial alkaline 
hydrolysis (type B gelatin) of animal collagen.  
 
Gelatin may also be a mixture of both types. The protein fractions consist 
almost entirely of amino acids joined together by amide linkages to form linear 
polymers, varying in molecular weight from 15 000–250 000.  
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Solubility 
Practically it is insoluble in acetone, chloroform, ethanol (95%), ether and 
methanol. But, soluble in glycerin, acids and alkalis, although strong acids or 
alkalis cause precipitation. In water, gelatin swells and softens, gradually 
absorbing between five and 10 times its own weight of water. Gelatin is soluble in 
hot water, forming a jelly, or gel, on cooling to 35–40°C. At temperatures >40°C, 
the system exists as a sol. This gel–sol system is heat-reversible, the melting 
temperature being slightly higher than the setting point; the melting point can be 
varied by the addition of glycerin. 
 
Viscosity (dynamic) 
9 4.3–4.7 cps for a 6.67% w/v aqueous solution at 60°C 
9 18.5–20.5 cps for a 12.5% w/v aqueous solution at 60°C 
 
Stability and Storage Conditions 
Dry gelatin is stable in air. Aqueous gelatin solutions are also stable for 
long periods if stored under cool, sterile conditions. At temperatures above about 
50°C, aqueous gelatin solutions may undergo slow depolymerization and a 
reduction in gel strength may occur on resetting. Depolymerization becomes more 
rapid at temperatures above 65°C, and gel strength may be reduced by half when a 
solution is heated at 80°C for 1 hour. The bulk material should be stored in an 
airtight container in a cool, dry place. 
 
Safety 
Gelatin is widely used in a variety of pharmaceutical formulations 
including oral and parenteral products. In general, when used in oral formulations 
gelatin may be regarded as a nontoxic and nonirritant material. 
Bloom Strength 
Various grades of gelatin are commercially available that differ in particle 
size, molecular weight, and other properties. Grading is usually by gel strength, 
expressed as ‘Bloom strength’, which is the weight in grams that, when applied 
under controlled conditions to a plunger 12.7 mm in diameter, will produce a 
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depression exactly 4 mm deep in a matured gel containing 6.66% w/w of gelatin 
in water. 
 
Acidity/alkalinity: (for a 1% w/v aqueous solution at 25°C) 
¾ pH = 3.8–6.0 (type A) 
¾ pH = 5.0–7.4 (type B) 
 
Density 
¾ 1.325 g/cm3 for type A 
¾ 1.283 g/cm3 for type B 
Isoelectric point 
¾ 7–9 for type A 
¾ 4.7–5.3 for type B 
Moisture content 
¾ 9–11% 
Functional Category 
Coating agent, film-former, gelling agent, suspending agent, tablet binder 
and viscosity increasing agent. 
 
 Applications in Pharmaceutical Formulation or Technology 
Gelatin is widely used in a variety of pharmaceutical formulations, 
including its use as a biodegradable matrix material in an implantable delivery 
system, although it is most frequently used to form either hard or soft gelatin 
capsules. 
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CHITOSAN 
Nonproprietary Names 
¾ BP  : Chitosan hydrochloride 
¾ PhEur : Chitosani hydrochloridum 
Synonyms 
¾ 2-Amino-2-deoxy-(1,4)-ß-D-glucopyranan; 
¾ Deacetylated chitin;  
¾ Deacetylchitin 
¾ ß-1,4-poly-D-glucosamine 
¾ poly-D-glucosamine 
¾ poly-(1,4-ß-D-glucopyranosamine) 
 
Chemical Name 
¾ Poly-ß-(1,4)-2-Amino-2-deoxy-D-glucose. 
 
Empirical Formula and Molecular Weight 
Partial deacetylation of chitin results in the production of chitosan, which 
is a polysaccharide comprising copolymers of glucosamine and N-
acetylglucosamine. Chitosan is the term applied to deacetylated chitins in various 
stages of deacetylation and depolymerization and it is therefore not easily defined 
in terms of its exact chemical composition. A clear nomenclature with respect to 
the different degrees of N-deacetylation between chitin and chitosan has not been 
defined and as such chitosan is not one chemical entity but varies in composition 
depending on the manufacturer. 
 
 In essence, chitosan is chitin sufficiently deacetylated to form soluble 
amine salts. The degree of deacetylation necessary to obtain a soluble product 
must be greater than 80–85%. Chitosan is commercially available in several types 
and grades that vary in molecular weight by 10,000–10,00,000 and vary in degree 
of deacetylation and viscosity. 
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Structural formula 
 
Figure.9  
Description 
Chitosan occurs as odorless, white or creamy-white powder or flakes. 
Fiber formation is quite common during precipitation and the chitosan may look 
'cotton like'. 
 
Typical properties 
 Chitosan is a cationic polyamine with a high charge density at pH <6.5; 
and so adheres to negatively charged surfaces and chelates metal ions. It is a linear 
polyelectrolyte with reactive hydroxyl and amino groups (available for chemical 
reaction and salt formation). The properties of chitosan relate to its polyelectrolyte 
and polymeric carbohydrate character. The presence of a number of amino groups 
allows chitosan to react chemically with anionic systems, which results in 
alteration of physicochemical characteristics of such combinations. 
 
Acidity/alkalinity: 
¾ pH = 4.0–6.0 (1% w/v aqueous solution) 
 
Density 
¾ 1.35–1.40 g/cm3 
 
Glass transition temperature 
¾ 203°C 
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Moisture content 
Chitosan adsorbs moisture from the atmosphere, the amount of water 
adsorbed depending upon the initial moisture content and the temperature and 
relative humidity of the surrounding air. 
 
Particle size distribution 
¾ <30µm 
 
Solubility 
Sparingly soluble in water; practically insoluble in ethanol(95%), other 
organic solvents, and neutral or alkali solutions at pH above approximately 6.5. 
Chitosan dissolves readily in dilute and concentrated solutions of most organic 
acids and to some extent in mineral inorganic acids (except phosphoric and 
sulfuric acids). 
 
 
Viscosity (dynamic) 
A wide range of viscosity types is commercially available. Owing to its 
high molecular weight and linear, unbranched structure, chitosan is an excellent 
viscosity-enhancing agent in an acidic environment. It acts as a pseudo-plastic 
material, exhibiting a decrease in viscosity with increasing rates of shear. The 
viscosity of chitosan solutions increases with increasing chitosan concentration, 
decreasing temperature, and increasing degree of deacetylation. 
 
 
Stability and Storage Conditions 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in a tightly closed container in 
a cool, dry place. The PhEur 2005 specifies that chitosan should be stored at a 
temperature of 2–8°C. 
 
 
Incompatibilities 
¾ Chitosan is incompatible with strong oxidizing agents. 
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Safety 
Chitosan is being investigated widely for use as an excipients in oral and 
other pharmaceutical formulations. It is also used in cosmetics. Chitosan is 
generally regarded as a nontoxic and nonirritant material. It is biocompatible with 
both healthy and infected skin. Chitosan has been shown to be biodegradable. 
LD50 (mouse, oral) : >16 g/kg 
 
Regulatory Status 
Chitosan is registered as a food supplement in some countries 
 
Functional Category 
Coating agent, disintegrant, film-forming agent, mucoadhesive, tablet 
binder, viscosity increasing agent. 
 
 
Applications in Pharmaceutical Formulation or Technology 
Chitosan is used in cosmetics and is under investigation for use in a 
number of pharmaceutical formulations. The suitability and performance of 
chitosan as a component of pharmaceutical formulations for drug delivery 
applications has been investigated in numerous studies. These include controlled 
drug delivery applications, use as a component of mucoadhesive dosage forms, 
rapid release dosage forms, improved peptide delivery, colonic drug delivery 
systems, and use for gene delivery.  
 
Chitosan has been processed into several pharmaceutical forms including 
gels, films, beads, microspheres, tablets, and coatings for liposomes. Furthermore, 
chitosan may be processed into drug delivery systems using several techniques 
including spraydrying, coacervation, direct compression and conventional 
granulation processes. 
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MATERIALS AND METHODS 
LIST OF MATERIALS 
List of Materials Used 
S.NO MATERIALS USED MANUFACTURER 
1. Dexibuprofen Shasun Pharmaceuticals Ltd., Puduchery. 
2. Sodium alginate Otto kemi, Mumbai. 
3. Gelatin Kemphasol, Mumbai. 
4. Chitosan Kemphasol, Mumbai. 
5. Sodium hydroxide Alba cheme, Chennai. 
6. Potassium dihydrogen Phosphate Alba cheme, Chennai. 
 
 
Table.1 
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LIST OF EQUIPMENTS 
List of Equipments Used 
S.No EQUIPMENTS  MANUFACTURER 
1. UV-Spectrophotometer Shimadzu 1700, Japan. 
2. FT-IR Perkin Elmer, USA. 
3. Electronic Balance Sartorius, Germany. 
4. pH Meter 
Elico L1120.Hyderabed, AP, 
India. 
5. Magnetic Stirrer Remi, Gujrat. 
6. 
Environment Stability 
Testing Chamber 
Heco Environment Chamber, 
Germany. 
7. SEM 
JSM-5610LV, Joel Ltd, Tokyo, 
Japan. 
 
Table.2 
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PREFORMULATION STUDIES 
 Preformulation test is the first step in the rational development of dosage 
forms of a drug substance. It can be defined as an investigation of physical and 
chemical properties of a drug substance alone and when combined with 
excipients. The overall objective of preformulation testing is to generate 
information useful to the formulator in developing stable and bioavailable dosage 
forms that can be man produced. 
 
The following preformulation studies are carried out: 
¾ Description 
¾ Solubility 
¾ Finding the absorption maxima 
¾ Standard curve 
¾ Infra red spectroscopy studies (compatibility studies) 
 
Description 
About 1g of sample is taken in a dry petridish and the sample is observed 
for compliance against the specification. 
 
 
Solubility Studies5 
The spontaneous interaction of two or more substance to form a 
homogeneous molecular dispersion is called as solubility. A semi quantitative 
determination of the solubility was made by adding solvent in small incremental 
amount to a test tube containing fixed quantity of solute or vice versa. After each 
addition, the system vigorously shaken and examined visually for any undisclosed 
solute particles. The solubility was expressed in turns of ratio of solute and 
solvent. 
 
The approximate solubility’s of substances are indicated by the descriptive 
terms in the accompanying table. The results were given in table 6. 
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Solubility profile I.P.1996 
 
DESCRIPTIVE TERM PARTS OF SOLVENT REQUIRED 
FOR 1 PART OF SOLUTE. 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10000 
Practically Insoluble or insoluble Greater than or equal to 10000 
Table.3 
Identification of Dexibuprofen 
Finding the absorption maxima (λmax) 
 The absorption maxima were found for drug identification. Ultraviolet 
Visible spectrophotometry has been used to obtain specific information on the 
chromophoric part of the molecules. Organic molecules in solutions when 
exposed to light in the Ultraviolet/visible region of the spectrum absorb light of 
particular wavelength depending on the type of electronic transition associated 
with the absorption. 
 
The drug solutions (µg/ml concentration) in 0.1N HCl was taken in a 
standard cuvette and scanned in the range of 200-400 nm in UV-
spectrophotometer. It exhibits absorption maxima at 222.0nm. Similarly, the 
procedure can be repeated for phosphate buffer pH 7.4. Maximum absorption was 
seen at 222.5nm. The results were given in figure 12 and 13. 
 
Standard Curve 
The drug solutions (10, 20, 30, 40, 50 and 60µg/ml in 0.1N HCl) were 
taken in a standard cuvette and scanned in the range of 200-400nm by using UV-
Spectrophotometer. The absorbance of each sample was measured at 222.0nm. 
The standard curve is plotted against absorbance and concentration of the sample. 
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Similarly, the procedure can be repeated for phosphate buffer pH 7.4. The results 
were given in table 7, 8 and figure 14. 
 
Fourier Transform Infrared (FTIR) spectral analysis 
 FT-IR is used to identify the functional groups in the molecule. The drug is 
mixed with KBr and a small thin pellet is formed. Each KBr pellet was scanned at 
4 m/s at a resolution of 2 cm over a wave number region of 400 to 4000 cm−1. The 
characteristic peaks were recorded. The results were given in table 9 to 15 and 
figure 15 to 21. 
 
Drug- Excipients Compatibility studies by FT-IR 
Fourier infrared spectroscopy (FT-IR) analysis was performed for the pure 
drug, polymer individually and then formulation and FT-IR was taken to find out 
that there is no interaction between drug and polymers. 
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FORMULATION OF BEADS 32, 40 
Composition of drug/polymer suspensions 
Each formulation contain 100mg of Dexibuprofen 
Formulation Sodium alginate 
(%w/v) 
Gelatin  
(%w/v) 
Chitosan 
 (%w/v) 
SA1 1 - - 
SA2 2 - - 
SA3 3 - - 
SA4 4 - - 
SAC0.5 3 0.5 - 
SAC1 3 1 - 
SAC1.5 3 1.5 - 
SAG0.5 3 - 0.5 
SAG1 3 - 1 
SAG1.5 3 - 1.5 
 
Table.4 
SA-Sodium alginate; SAC-Sodium alginate with Chitosan;  
SAG-Sodium alginate with Gelatin; 0.5,1,1.5,2,3,4 indicate the percentage. 
Composition of dispersing medium for 100ml 
9 3ml of methanol 
9 1ml of formaldehyde 
9 8ml of HCl 
9 Distilled water upto 100 ml 
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Formulation of Dexibuprofen Hydrogel beads by Ionotropic gelation method 
using Formaldehyde as cross-linking agent 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.10 
 
% solution of (Sodium alginate + Chitosan / Gelatine) 
Dispersion of drug into solution 
Uniform suspension 
Injection of drug-polymer suspension into dispersion medium 
Stirred at 50 rpm 
Filtered and washed with distilled water 
Dried at room temperature 
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Wet Hydrogel Bead 
 
Figure.11 
EVALUATION OF BEAD 
Particle Size Measurement61 
Determination of particle size by optical microscopy 
A few numbers of beads were transferred on the glass slide and was 
focused in microscope. By using eyepiece micrometer, the diameter of beads is 
determined. The results were given in table 15 and figure 30. 
 
Standardization of eyepiece micrometer 
6 division of the eyepiece micrometer scale coincide with 8 division of 
stage micrometer. 
 
One division of stage micrometer =10 µm 
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No .of division of stage 
        micrometer 
Hence one division of eyepiece micrometer =    ----------------------------------- X 10 
No. of division of eyepiece        
micrometer 
 
Scanning electron microscopy29 
The purpose of the Scanning Electron Microscopy study was to obtain a 
topographical characterization of beads. Scanning electron micrographs were 
obtained by scanning the surface of samples with high energy beam of electrons. 
The beads were mounted on brass stubs using double-sided adhesive tape. 
Scanning electron microscopy photographs were taken with a scanning electron 
microscope (JSM-5610LV, Joel Ltd, Tokyo, Japan) at the required magnification 
at room temperature. The working distance was maintained, and the acceleration 
voltage used was 15 kV, with the secondary electron image as a detector. The 
results were given in figure 33. 
 
Gelling rate32 
 The gelling rate is performed during particle formation. After dropping 
suspension, which contains drug and polymer, into the dispersion medium contain 
cross-linking agent, beads were collected at appropriate time intervals. Beads are 
weighed after removal of moisture from the surface with filter paper. The results 
were given in table 16 to 18 and figure 33 to 35. Results are expressed in % 
weight loss. 
 
Weight after removal of moisture 
% Weight Loss = -------------------------------------------X 100 % 
       Initial Weight of beads 
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Determination of Drug Content and Entrapment Efficiency18, 32 
Drug content and the Entrapment efficiency are important parameters. 
During cross-linking polymer and/or polymer-polymer, there is possibility of 
leaching of drug into dispersion medium. The entrapment efficiency (%) of 
hydrogel beads was determined spectrophotometrically at a wavelength of 
maximum absorbance (λmax=222.5nm) using a spectrophotometer (Shimadzu 
1700, Japan) by measuring amount of drug left in the solution during the synthesis 
of beads. The results were given in table 19 and figure 36. The entrapment 
efficiency was calculated as: 
 
[C1-C2] 
Entrapment efficiency (%) =     --------------- X 100% 
    C1 
 Where, C1 is the known concentration of Dexibuprofen in polymer 
solution that is amount Dexibuprofen taken for formulation and C2 is the 
concentration of Dexibuprofen in dispersion medium. 
 
In vitro release profile35 
 The dissolution studies were carried out using USB baskets (Type I) 
apparatus at 50rpm and 37±0.5°C. The beads were filled into colorless hard 
gelatin capsules and placed in basket separately. The dissolution medium was 0.1 N 
HCl having pH 1.2 as simulated gastric fluid (SGF) for the first 2 hour, followed by 
phosphate buffer pH 7.4 as simulated intestinal fluid (SIF) for the next 10 hour.  
 
5 ml samples were withdrawn at specific time intervals and replaced 
immediately with an equal volume of fresh medium. Samples were assayed by 
UV-spectrophotometry, using a spectrophotometer (Shimadzu 1700, Japan).From 
the absorbance values, the cumulative percent release were determined. The 
results were given in table 20 and figure 27. 
 
 
 
 FORMULATION AND EVALUATION 
 
   61 
 
Dissolution Study 
Apparatus  :  USP Type I  
Speed   : 50rpm 
Temperature  :  37±0.5°C 
Medium :  0.1N HCl for 2 hour followed by Phosphate                   
buffer pH 7.4 upto hour  
 
Swelling studies18,32 
Known weight of the beads were taken and immersed in excess of 
Phosphate buffer pH 7.4 for definite time interval at 37 ◦C and then beads were 
removed and weighed immediately. The difference in weight gave the amount of 
water uptake by the beads after definite time intervals (30 min). The results were 
given in table 21 to 24 and figure 39 to 42. The percentage swelling (Ps) of the 
beads was calculated as: 
Ws-Wd 
Percentage Swelling (Ps) =------------------X100 
            Wd  
Where, Ws is the weight of swollen bead. 
 Wd is the weight of dry bead. 
 
 
 
KINETICS OF DRUG RELEASE10,12 
Analysis of release profiles 
The rate and mechanism of release of both drugs from the prepared matrix 
beads were analyzed by fitting the dissolution data into the zero-order equation. A 
plot of Cumulative % drug release versus time would be linear if the drug release 
follows zero order. (ie. Concentration independent release) 
 
Zero order equation 
Q=k0t 
Where, Q is the amount of drug released at time t 
 k0 is the release rate constant,  
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First order equation 
A plot of log of % remaining drug versus time would be linear, if the drug 
release follows first order (ie. Concentration dependent release) 
 
ln (100-Q)=ln100-K1t 
Where, k1 is the release rate constant. 
 
Higuchi’s equation 
Q=K2t1/2 
Where, k2 is the diffusion rate constant. 
Peppas equation 
The mechanism of swelling and drug release has been discussed in 
detailed in our earlier study. Swelling of the polymers and the drug release profile 
from the polymer have been classified into three types of diffusion mechanisms on 
the basis of relative rate of diffusion of water into polymer matrix and rate of 
polymer chain relaxation. In case of water uptake, the weight gain, Ms, is 
described by following equation. 
Ms=Ktn 
where, n is the release exponent indicative of the mechanism of release, 
Ms is weight gain,  
t is the release time,  
k is the kinetic constant. 
 
Fickian diffusion 
Normal Fickian diffusion is characterized by n = 0.5, while Case II 
diffusion by n = 1.0. A value of n between 0.5 and 1.0 indicates a mixture of 
Fickian and Case II diffusion, which is usually called non-Fickian or anomalous 
diffusion. The above power law expression could be used for the evaluation of 
drug release from swellable systems. 
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In this case, Mt/M∞ replace Ms in above equation to give equation.  
 
Mt/M∞=Ktn 
 
where Mt/M∞ is the fractional release of drug in time t, ‘k’ is the constant 
characteristic of the drug–polymer system, and ‘n’ is the diffusion exponent 
characteristic of the release mechanism. Mt and M∞ is drug released at time‘t’ 
and at equilibrium respectively. The results were given in table 25 and figure43. 
 
ACCELERATED STABILITY STUDIES16,43,44 
Stability 
Stability is officially defined as the time lapse during which the drug 
product retains the same property and characteristics that it possessed at the time 
of manufacture. This process begins at early development phases.  
 
 
Definition 
Stability of a pharmaceutical preparation can be defined as “the capability 
of a particular formulation (dosage form or drug product) in a specific 
container/closure system to remain within its physical, chemical, microbiological, 
therapeutic and toxicological specifications throughout its shelf life.  
 
Instability in modern formulation is often undetectable only after 
considerable storage period under normal conditions. To assess the stability of a 
formulated product, it is usual to expose it to high stress conditions to enhance 
deterioration and therefore the time required for testing is reduced. 
 
 Common high stress factors are temperature and humidity. This will 
eliminate unsatisfactory formulation. 
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Purpose of stability testing 
¾ To study of drug decomposition kinetics 
¾ To develop stable dosage form 
¾ To establish the shelf life or expiration date for commercially available 
drug product. 
¾ To ensure the efficacy, safety and quality of active drug substance and 
dosage forms. 
Stability Conditions Chart 
 
S.No 
 
Study 
Storage 
Condition 
 
Minimum Period 
1. Long-term 25°C±2°C 
60%±5% 
12 Months 
2. Intermediate 30°C±2°C 
60%±5% 
6 Months 
3. Accelerated 40°C±2°C 
75%±5% 
6 Months 
 
Table.5 
 
Procedure for Accelerated Stability Studies: 
Selected batches were placed in a high density polyethylene container 
along with wrapper. They are kept in stability chamber maintained at 40ºc and 
75% RH. The stability studies were carried out for a period of three months. The 
beads were tested and checked at regular intervals for changes in percentage of 
drug content. The results were given in table 26. 
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Results and discussion 
Preformulation studies 
Description : White, Odourless powder 
Solubility : 
 
Solubility Profile of Dexibuprofen 
 
S. NO SOLVENT SOLUBILITY 
 
 
1. Chloroform Very soluble 
2. Water Slightly Soluble 
3. Alcohol Soluble 
4. Ether Very soluble 
 
Table.6 
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Identification of Dexibuprofen in 0.1N HCl 
 
 
Identification of λmax for Dexibuprofen in 0.1N HCl 
 
Figure.12 
It exhibits absorption maxima at 222.0nm 
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Identification of Dexibuprofen in Phosphate buffer pH 7.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of λmax for Dexibuprofen in phosphate buffer pH 7.4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.13 
It exhibits absorption maxima at 222.5nm. 
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Standard Curve 
Standard curve in 0.1N HCl 
S.No Concentration 
(µg/ml) 
Absorbance 
at 222.0 nm 
1. 0 0 
2. 10 0.0546 
3. 20 0.1120 
4. 30 0.1498 
5. 40 0.1880 
6. 50 0.2487 
7. 60 0.2958 
Table.7 
a=0.0249, b=0.0041,   r=0.996 
Standard curve in 0.1N HCl 
 
Figure 14 
The Standard curve has good regression coefficient(r=0.996) and it 
shows the linearity. 
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Standard curve in phosphate buffer pH7.4 
S.No Concentration 
(µg/ml) 
Absorbance 
at 222.5 nm 
1. 0 0 
2. 10 0.0564 
3. 20 0.1040 
4. 30 0.1504 
5. 40 0.1996 
6. 50 0.2467 
7. 60 0.2926 
Table.8 
a=0.0247, b=0.0045,   r=0.9990 
Standard curve in phosphate buffer pH7.4 
 
Figure.15 
The Standard curve has good regression coefficient(r=0.9990) and it 
shows the linearity. 
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FTIR 
FTIR spectra of Dexibuprofen 
 
Figure.16 
FT-IR spectral assignments for the pure drug Dexibuprofen 
 
Wave number in cm-1 Assignment 
2658.56 Aliphatic C-H Stretching 
1122.52 C-O Stretching 
1152.68 C=O Stretching 
653.59,585.69,522.62 C-H out of plane bending 
 
Table.9 
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FTIR spectra of Sodium Alginate 
 
 
 
 
 
 
 
 
 
 
 
Figure.17 
FTIR spectral assignments for Sodium Alginate 
 
Wave number in cm-1 Assignment 
3405.03 O-H Stretching 
2137.75 C-H Stretching 
1097.58 C=O Stretching 
1033.05 C-O Stretching 
816.95 C-H out of plane bending 
 
Table.10 
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FTIR spectra of Chitosan 
 
Figure.18 
 
FT-IR spectral assignments for Chitosan 
 
Wave number in cm-1 Assignment 
2348.64 Aliphatic C-H stretching 
3415.62,3341.75 Aliphatic O-H stretching 
2935.36 N-H stretching 
1415.34 O-H deformation  
 
Table.11 
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FTIR spectra of Gelatin 
 
 
 
Figure.19 
 
FT-IR spectral assignments for Gelatin 
 
Wave number in cm-1 Assignment 
2935.36 N-H Stretching 
2348.64 Aliphatic C-H Stretching 
662.68 C-H out of plan bending 
 
Table.12 
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FTIR Spectra of Sodium Alginate beads 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.20 
 
FT-IR spectral assignments for Sodium Alginate beads 
 
Wave number in cm-1 Assignment 
3563.87 O-H Stretching 
2650.87 C-H Stretching 
1058.20 C=O Stretching 
686.65,770.28 C-H out of plan bending 
 
Table.13 
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FTIR Spectra of Sodium Alginate-Chitosan beads 
 
Figure.21 
 
FT-IR spectral assignments for Sodium Alginate-Chitosan beads  
 
Wave number in cm-1 Assignment 
3791.25 Aliphatic O-H stretching 
2951.10 N-H stretching 
 
Table.14 
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FTIR Spectra of Sodium Alginate-Gelatin beads 
 
Figure.22 
 
FT-IR spectral assignments for Sodium Alginate-Gelatin beads  
 
Wave number in cm-1 Assignment 
1379.91 C-O-O Stretching 
2347.49 Aliphatic C-H Stretching 
2927.84 N-H Stretching 
 
Table.15 
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Determination of Particle size by microscopic method 
The prepared formulations are taken for the microscopic analysis. It 
reveals that the prepared beads are in the size range of 1.55mm to 1.94mm. 
Particle size analysis 
S.No. Formulation Mean diameter in 
mma 
1 SA1 1.62 ±0.02 
2 SA2 1.75 ±0.03 
3 SA3 1.88 ±0.02 
4 SA4 1.94 ±0.01 
5 SAC0.5 1.59 ±0.04 
6 SAC1 1.83 ±0.03 
7 SAC1.5 1.69 ±0.02 
8 SAG0.5 1.79 ±0.03 
9 SAG1 1.55 ±0.03 
10 SAG1.5 1.91 ±0.02 
a Mean ± S.D.; n=3 
Table.16 
Comparative Particle size analysis 
 
Figure.23 
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SEM PHOTOMICROGRAPH OF ALGINTE-CHITOSAN BEAD 
 
 
 
 
 
Figure.24 
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Gelling rate for formulation SA1 to SA4 
 
Time in 
Minute 
Percentage weight lossa (%) 
SA1 SA2 SA3 SA4 
0 100 100 100 100 
5 80.42±1.4 68.59±1.2 55.94±0.9 55.83±0.9 
10 68.28±1.2 53.74±0.9 44.94±0.7 43.82±0.7 
15 56.84±0.9 46.73±0.8 42.93±0.6 41.83±0.6 
20 48.95±0.7 43.25±0.7 41.64±0.6 40.72±0.6 
30 42.10±0.6 42.93±0.6 41.94±0.6 40.38±0.6 
45 42.82±0.6 42.94±0.6 41.92±0.6 40.73±0.6 
a Mean ± S.D.; n=3 
 
Table.17 
 
 
Comparative Gelling rate profile for formulation SA1 to SA4 
 
 
Figure.25 
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Gelling rate for formulation SAC0.5 to SAC1.5 
 
Time in 
Minute 
Percentage weight lossa (%) 
SAC0.5 SAC1.0 SAC1.5 
0 100 100 100 
5 81.36±1.4 78.60±1.0 80.93±1.4 
10 61.03±0.9 58.83±0.9 60.03±0.9 
15 51.29±0.7 50.65±0.8 52.67±0.9 
20 43.94±0.6 46.29±0.7 45.98±0.7 
30 41.38±0.6 41.94±0.6 43.97±0.6 
45 41.56±0.6 41.56±0.6 41.54±0.6 
a Mean ± S.D.; n=3 
 
Table.18 
 
Comparative Gelling rate profile of formulation SAC0.5 to SAC1.5 
 
Figure.26 
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Gelling rate of formulation SAG0.5 to SAG1.5 
 
Time in 
Minute 
Percentage weight lossa (%) 
SAG0.5 SAG1.0 SAG1.5 
0 100 100 100 
5 68.83±1.27 72.63±1.34 70.73±1.25 
10 50.65±0.73 48.63±0.81 45.36±0.74 
15 43.75±0.78 42.56±0.74 40.38±0.71 
20 40.38±0.72 41.74±0.76 40.74±0.70 
30 38.12±0.67 38.18±0.63 38.59±0.66 
45 38.41±0.61 38.23±0.60 37.93±0.58 
a Mean ± S.D.; n=3 
 
Table.19 
Comparative Gelling rate profile of SAG0.5 to SAG1.5 
 
 
Figure.27 
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Determination of Entrapment Efficacy 
S.No. Formulation % Entrapment Efficacya 
1. SA1 63.45±1.23 
2. SA2 68.20±0.94 
3. SA3 72.10±0.87 
4. SA4 67.02±0.34 
5. SAC0.5 76.64±0.93 
6. SAC1 79.73±0.74 
7. SAC1.5 82.42±1.09 
8. SAG0.5 69.92±0.89 
9. SAG1 69.37±0.92 
10. SAG1.5 68.82±0.79 
a Mean ± S.D.; n=3 
Table.20 
Comparative Entrapment efficiency for all formulation 
 
 
Figure.28 
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Dissolution Study 
Comparative In-vitro drug release profile for all formulation  
 
Time 
in 
hour 
a CUMULATIVE PERCENTAGE DRUG RELEASE  (%)  
SA1 SA2 SA3 SA4 SAC0.5 SAC1 SAC1.5 SAG0.5 SAG1 SAG1.5 
0 0 0 0 0 0 0 0 0 0 0 
0.5 1.98±0.04 1.72±0.03 1.37±0.37 1.63±0.03 1.12±0.12 1.13±0.94 1.19±0.38 1.72±0.63 1.02±0.04 1.72±0.51 
1 2.92±0.06 2.56±0.13 2.83±0.74 2.83±0.82 2.10±0.09 2.32±0.62 2.65±1.03 2.82±0.30 2.03±0.82 2.82±0.64 
2 4.28±0.02 3.28±0.30 3.20±0.63 3.29±0.63 4.23±0.03 4.12±0.47 4.25±0.94 3.82±.83 5.43±0.25 3.74±0.37 
3 27.38± 0.74 29.96±1.03 22.74±0.94 30.83±0.35 11.38±0.34 12.65±0.38 13.93±0.72 10.29±0.93 10.93±0.56 10.29±0.72 
4 43.03± 1.23 45.93±1.12 50.84±0.47 52.63±0.26 20.35±0.73 18.85±0.36 19.75±0.93 16.98±0.71 16.63±0.48 14.98±0.74 
5 66.85± 0.95 69.06±1.02 61.83±0.64 62.84±0.83 25.63±0.46 23.75±0.27 26.69±0.74 19.02±1.02 21.93±0.82 19.02±0.01 
6 80.03± 0.93 82.72±0.94 70.38±0.73 71.82±0.83 28.25±0.72 29.45±0.36 31.74±1.82 22.82±0.35 24.83±0.45 20.84±0.83 
7   74.73± 75.83±0.93 34.63±0.93 35.86±0.98 38.63±0.73 25.73±0.62 27.73±0.92 23.93±0.83 
8     36.74±0.37 38.97±1.02 42.94±0.92 27.83±0.26 30.37±0.27 24.37±0.82 
9     42.28±0.95 44.69±0.27 48.69±0.45 30.92±0.62 32.82±0.34 26.39±0.45 
10     44.93±0.28 48.83±0.46 52.83±0.82 31.24±0.09 33.98±0.27 29.03±0.71 
11     45.99±0.38 52.63±0.28 56.63±0.48 32.02±0.12 34.37±0.83 30.39±0.93 
12     48.48±0.82 54.48±0.37 61.48±0.73 33.01±0.86 35.48±0.35 31.03±0.57 
a Mean ± S.D.; n=3 
Table 21
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Comparative in-vitro release profile for all formulation 
 
 
Figure.29 
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Comparative Swelling studies for SA1 to SA4 
 
Time in 
minute 
Percentage swelling a 
SA1 SA2 SA3 SA4 
0 0 0 0 0 
10 42.03±0.89 40.37±0.38 38.03±1.31 41.93±0.93 
20 80.94±0.85 82.82±0.74 78.02±0.83 80.93±0.94 
30 107.03±0.85 106.03±0.38 110.93±0.74 112.92±0.48 
45 130.83±0.95 128.94±0.84 136.83±0.93 133.93±0.84 
60 140.72±0.38 142.93±0.83 148.82±1.30 148.27±0.84 
90 151.92±0.38 152.83±1.02 154.94±0.83 155.88±0.84 
a Mean ± S.D.; n=3 
Table.22 
Comparative Swelling studies for SA1 to SA4 
 
 
Figure.30 
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Swelling studies for SAC0.5 to SAC1.5 
 
Time in minute Percentage swelling a (%) 
SAC0.5 SAC1.0 SAC1.5 
0 0 0 0 
10 10.94 ±0.36 12.64 ±0.93 11.84 ±0.83 
20 22.78 ±0.27 21.34 ±0.27 23.93 ±0.37 
30 34.67 ±0.89 33.12 ±0.84 34.83 ±1.02 
45 47.36 ±0.77 48.83 ±0.37 49.63 ±0.83 
60 51.27 ±0.95 56.49 ±0.85 53.93 ±0.47 
90 53.83 ±1.04 57.78 ±0.94 55.83 ±0.38 
a Mean ± S.D.; n=3 
Table.23 
Comparative Swelling studies for SAC0.5 to SAC1.5 
 
 
 
Figure.31 
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Swelling studies for SAG0.5 to SAG1.5 
 
Time in minute Percentage swelling a 
SAG0.5 SAG1.0 SAG1.5 
0 0 0 0 
10 20.26 ± 1.02 18.34 ± 0.74 19.73 ± 0.84 
20 30.93 ± 0.98 29.63 ± 0.59 28.74 ± 0.74 
30 48.73 ± 0.82 46.27 ± 0.60 45.83 ± 0.78 
45 60.68 ± 0.92 62.68 ± 0.58 60.67 ± 0.84 
60 65.91 ± 0.53 66.76 ± 0.84 65.83 ± 1.93 
90 68.94 ± 0.57 69.35 ± 0.83 69.84 ± 0.56 
a Mean ± S.D.; n=3 
Table.24 
 
Comparative Swelling studies for SAG0.5 to SAG1.5 
 
 
Figure.32 
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Comparative Swelling studies for all formulation 
Time 
in 
minute 
Percentage Swelling a 
 
SA1 SA2 SA3 SA4 SAC0.5 SAC1.0 SAG1.5 SAG0.5 SAG1.0 SAG1.5 
0 0 0 0 0 0 0 0 0 0 0 
10 42.03 
±0.89 
40.37± 
0.38 
38.03±1.31 41.93±0.93 10.94 ±0.36 12.64 ±0.93 11.84 ±0.83 20.26 ± 1.02 18.34 ± 0.74 19.73 ± 0.84 
20 80.94 
±0.85 
82.82± 
0.74 
78.02±0.83 80.93±0.94 22.78 ±0.27 21.34 ±0.27 23.93 ±0.37 30.93 ± 0.98 29.63 ± 0.59 28.74 ± 0.74 
30 107.03 
±0.85 
106.03± 
0.38 
110.93±0.74 112.92±0.48 34.67 ±0.89 33.12 ±0.84 34.83 ±1.02 48.73 ± 0.82 46.27 ± 0.60 45.83 ± 0.78 
45 130.83 
±0.95 
128.94± 
0.84 
136.83±0.93 133.93±0.84 47.36 ±0.77 48.83 ±0.37 49.63 ±0.83 60.68 ± 0.92 62.68 ± 0.58 60.67 ± 0.84 
60 140.72 
±0.38 
142.93± 
0.83 
148.82±1.30 148.27±0.84 51.27 ±0.95 56.49 ±0.85 53.93 ±0.47 65.91 ± 0.53 66.76 ± 0.84 65.83 ± 1.93 
90 151.92 
±0.38 
152.83± 
1.02 
154.94±0.83 155.88±0.84 53.83 ±1.04 57.78 ±0.94 55.83 ±0.38 68.94 ± 0.57 69.35 ± 0.83 69.84 ± 0.56 
Table.25 a Mean ± S.D.; n=3 
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Comparative Percentage Swelling for all Formulation 
 
 
Figure 33 
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Kinetics of drug release 
 
Results of curve fitting of the in-vitro dexibuprofen release data from different 
hydrogel beads in simulated intestinal fluid. 
 
 
Formulation 
Code 
Correlation coefficient (r2) ‘n’-
Release 
Exponent 
Zero order
[r] 
First order
[r] 
Higuchi 
[r] 
Korsmeyer- 
Peppas [r] 
SAC0.5 0.929 0.912 0.933 0.836 0.723 
SAC1.0 0.956 0.908 0.911 0.838 0.823 
SAC1.5 0.994 0.931 0.955 0.895 0.961 
SAG0.5 0.974 0.913 0.935 0.919 0.689 
SAG1.0 0.905 0.929 0.947 0.728 0.801 
SAG1.5 0.975 0.956 0.956 0.886 0.799 
 
Table.26 
 
n =  Diffusion exponent related to mechanism of drug release,  
  according to equation Mt/M∞=K t n,  
r = Correlation coefficient 
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Figure.34 
Release Kinetics for Formulation SAC0.5 
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Release Kinetics for Formulation SAC1.0 
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Release Kinetics for Formulation SAC1.5 
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Release Kinetics for Formulation SAG0.5 
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Release Kinetics for Formulation SAG1.0 
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Release Kinetics for Formulation SAG1.5 
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Stability Study 
 
 
S.No. 
 
Formulation 
 
Before 
storage 
Stored at 40°C ± 2°C and 
75% ± 5% RH 
First month Second 
month 
Third 
month 
1. SAC1.5 75.42% 73.02% 72.40% 70.10% 
 
Table.27 
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Discussion 
The efforts of many researchers have been concerned to solve problems of 
NSAID that are mainly at the gastric level are well known, following oral 
administration, through a variety of techniques of protection of the gastric mucosa or 
alternatively to prevent the NSAID release in this gastric region.  
 
In the present work, with the potential utility of polymer, such as sodium 
alginate, chitosan and gelatin were investigated in controlling the release of 
dexibuprofen in simulated intestinal environment. Since among the multiparticulate 
systems, hydrogel beads have a special interest as carriers for NSAID, mainly to 
extend the duration of the dosage form, aimed to investigate possible applicability of 
sodium alginate hydrogel beads with Gelatin and Chitosan as drug release modifiers 
to get sustained release system.  
 
Prepared beads containing dexibuprofen by ionotropic gelation method were 
examined the effects of various factors (concentration of sodium alginate, 
concentration of polymer ratio [Chitosan and/or gelatin], curing time i.e., Gelling 
rate and swelling studies).  
 
The beads were prepared by dropping a mixture of colloidal copolymer 
suspension containing dexibuprofen into the methanol containing formaldehyde 
dispersion medium, in which formaldehyde acted as a cross-linking agent. The 
droplets instantaneously form a gel like bead due to cross-linking of formaldehyde 
with the polymer. Formulations were given in table 4. 
  
The reaction between polymer and formaldehyde to form hydrogel beads 
were utilized for development of new matrix system containing dexibuprofen. In 
particular, the N-H group, this would be the most probable to react with an aldehyde. 
The beads were collected, filtered, washed to remove the impurities and dried at 
room temperature.  
 
The IR spectra of the drug and polymer were compared with the spectra of 
the pure drug and individual polymers in which no shifting of peaks was 
significantly found, indicating the stability of the drug during encapsulation process. 
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In an attempt to determine the minimum necessary exposure time (curing 
time), the extent of ionotropic gelation was indirectly assessed through the weight 
variation corresponding to water loss during matrix formation. Determination of 
gelling rate allows the evaluation of speed and degree of polymer reaction on the 
formation of reticulated structure as show in Table 17, 18, 19 and Figure 25, 26, 27. 
The reaction between the polymer and formaldehyde is fairly rapid being completed 
at the end of 30 minute. Total amount of water expelled out was same for all 
formulations studied (approximately 50% of initial weight of wet bead) suggesting 
that a 30-min curing period is adequate to obtain cross-linked alginate beads. 
 
The mean particle size of drug loaded beads were analysed by Optical 
microscopy. Drug incorporation leads to increase in particle size, and so 
dexibuprofen containing beads have a mean size range from 1.59 to 1.94mm. From 
the SEM analysis for SAC1.5, size was found to be 1.6mm.      
 
The physical parameter like shape, size and surface morphology were 
analysed by SEM (Scanning Electron Microscopy) for formulation SAC0.5, SAC1.0 
and SAC1.5. During particle drying, the beads were spherical in shape, which is 
confirmed by SEM in figure 24 for SAC1.5. Microscopy analysis shows that beads 
prepared with formaldehyde shows spherical in shape. The inclusion of polymer in 
matrix creates beads with smooth surface. In addition, no particle aggregation was 
found in the formulation, owing to cross-linking reaction. 
 
 
Encapsulation efficacy was performed for all formulation. Results were 
given in table 20 and figure 28. Among them, formulation SAC1.5 shows maximum 
entrapment efficacy [82.42%]. The results indicated that drug content was more in 
SAC1.5. 
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All formulations were studied for dissolution test for a period of 12 hours. 
Comparative studies of drug from all prepared formulation were tabulated in Table 
21. From the comparative profile, Beads with sodium alginate alone (SA1 to SA4) 
does not extent drug release much more when compared to bead with chitosan and 
gelatin polymer. Beads with chitosan and gelatin polymer extend the drug release 
over the period of time. Chitosan start dissolve only in acidic medium. But alginate 
starts at alkaline medium. These two polymer combination extend drug release when 
compared to gelatin combination. When a cross-linking agent was added to polymer, 
thus promoting bonding between polymer chains, the release behavior was different, 
suggesting a change in the matrix structure with new characteristics. Among the 6 
formulation (SAC0.5, SAC1.0, SAC1.5, SAG0.5, SAG1.0, SAG1.5), maximum 
percentage of 61.48% were obtained from the formulation SAC1.5 during 12 hours. 
Dexibuprofen release was significantly sustained in phosphate buffer pH 7.4 for the 
formulation of SAC1.5.  
 
Swelling behaviour of beads indicates the speed and easiness of a liquid to 
penetrate the hydrogel matrix, as a necessary to retard the drug release from the 
matrix. These studies indicate swelling of beads during dissolution process. As show 
in Table 22 to 25 and Figure 30 to 33, percentage swelling of bead(around 150%) 
with sodium alginate alone(SA1 to SA4) increases much more than bead with 
chitosan and gelatin. Controlled swelling indicates the sustained release of drug from 
the formulation SAC0.5 to SAC1.5 and SAG0.5 to SAG1.5. Among the formulation 
SAC0.5, SAC1.0, SAC1.5, SAG0.5, SAG1.0, SAG1.5, beads with chitosan shows 
controlled swelling. 
 
 The in vitro drug release data of beads, obtained by ionotropic gelation 
technique with chitosan and gelatin containing dexibuprofen, were evaluated 
kinetically using various mathematical models like Zero order, First order, Higuchi, 
and Korsmeyer-Peppas model. The results of the curve fitting of these above-
mentioned mathematical models are given in Table 26 and Figure 34.  
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When respective correlation coefficients of these beads in simulated 
intestinal fluid were compared, the dexibuprofen release from these beads was found 
to follow Zero order (r2 = 0.973–0.993) over a period of 12 h. The value of release 
exponent (n) determined from in vitro drug release data of various dexibuprofen 
loaded cross-linked hydrogel beads ranged from 0.689 to 0.961 in simulated 
intestinal fluid, indicating anomalous (non-Fickian) diffusion mechanism for drug 
release. The anomalous diffusion mechanism of drug release demonstrates both 
diffusion controlled, and swelling controlled drug release from cross-linked hydrogel 
beads containing dexibuprofen. 
 
A stability study of the formulation (SAC1.5) was carried out for three month 
as per standard procedure. During this period the formulation showed without 
significant change in drug content. 
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Conclusion: 
Based on the literature survey, dexibuprofen was selected for the research 
work. The results herein presented indicate that a new dexibuprofen-loaded cross-
linked hydrogel beads [SAC1.5] were obtained with high encapsulation efficiency 
and good sustained release over 12 hours presenting promising characteristics as 
compared to conventional calcium alginate beads from previous studies.  
The use of polymer combination successfully delays dexibuprofen release, 
which can be tailored to produce a suitable single dose administration per day. 
 Physicochemical characterization demonstrates the formation of a new 
hydrogel matrix shows that dexibuprofen does not interfere with the new matrix 
hydrogel formation process.  
Therefore, matrix modification by an appropriate method, such as suitable 
cross-linking reaction, is crucial in the controlled release of dexibuprofen from 
hydrogel beads.  
The formulation SAC1.5 has achieved the objective of sustained cross-
linked hydrogel beads. 
The ionotropic gelation method for the preparation of these cross-linked 
hydrogel beads containing dexibuprofen system for oral delivery was found to be 
simple, reproducible, easily controllable, economical and consistent process.  
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